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"I believe in evidence. I believe in observation, measurement, and 
reasoning, confirmed by independent observers. I'll believe anything, no matter 
how wild and ridiculous, if there is evidence for it. The wilder and more ridiculous 
something is, however, the firmer and more solid the evidence will have to be." 
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Difficulties in the access and effective treatment of sheltered intracellular 
bacterial infections may potentially be overcome by encapsulating drugs into 
delivery systems functionalised with bacteria-derived invasive proteins. Although 
the potential of these proteins is clear, the promising application and indeed 
characteristics of invasive particles remains to be fully explored. The objectives of 
this study were therefore to determine the influence of shape on bacteriomimetic 
system characteristics, using invasive spherical and aspherical polymeric 
nanocarriers. Aspherical nanoparticles were prepared by an optimised combination 
of chemical functionalisation and thermomechanical stretching. InvA497, a C-
terminal fragment of the Yersinia-derived protein invasin, was covalently coupled 
onto the surface of both spherical and aspherical nanoparticles. In vitro studies 
using drug-free nanoparticles indicated shape-dependent differences on receptor-
mediated uptake by epithelial cells, being slightly faster for spherical nanoparticles. 
Both types of nanoparticles were then loaded with a preparation of antibiotic 
gentamicin, and tested for their ability to kill intracellular Shigella flexneri in human 
epithelial cells. Aspherical systems led to a higher killing of intracellular bacteria, 
potentially due to a more favorable drug release profile. This study provides a 
proof of concept that InvA497-functionalised aspherical bacteriomimetic 
nanocarriers may efficiently deliver otherwise non-permeable antibiotics across 






Eine wirksame Behandlung von intrazellulärer lokalisierten und auf diese 
Weise geschützten bakteriellen Infektionen kann mit Hilfe von spezieller 
nanopartikulären Systemen, die mit invasiven, von Bakterien abgeleiteten 
Proteinen funktionalisiert sind, erreicht werden. Obwohl das Potenzial dieser 
Proteinen bereits bekannt ist, sind vielversprechende Anwendungen und 
Eigenschaften dieser bakteriomimetischen Transportsysteme noch gründlich zu 
erforschen. 
Ziel dieser Arbeit war es, den Einfluss von zwei unterschiedlichen 
Partikelformen (sphärisch und asphärisch) auf die Wirksamkeit dieser 
bakteriomimetischen Systeme zu untersuchen. Asphärische Nanopartikel wurden 
durch eine optimale Kombination von chemischer Funktionalisierung und 
thermomechanischer Dehnung vorbereitet. InvA497, ein C-Endfragment des 
invasiven, von Yersinia abgeleiteten Proteins «Invasin», wurde kovalent an die 
Nanopartikeloberfläche gekoppelt. In vitro Untersuchungen mit wirkstofffreien 
Nanopartikeln zeigten formabhängige Unterschiede in der Rezeptor-vermittelten 
Aufnahme bei Epithelzellen Hep-2. Bei sphärischen Nanopartikeln war die 
Aufnahme etwas schneller. Beide Nanopartikelsysteme wurden daraufhin mit dem 
Antibiotikum Gentamicin geladen und auf deren Fähigkeit geprüft, intrazelluläre 
Shigella flexneri Erreger in menschlichen Epithelzellen zu töten. Asphärische 
Systeme zeigten eine höhere Fähigkeit zur Abtötung der intrazellulären Bakterien, 
möglicherweise bedingt durch ein vorteilhaftes Wirkstofffreisetzungsprofil. 
Mit dieser Untersuchung konnte nachgewiesen werden, dass InvA497-
funktionalisierte, asphärische, bakteriomimetische Nanoträger nicht permeable 
Antibiotika durch die Wirtszellmembran effizient transportieren können, um 








1.1 BACTERIAL INFECTION: A NEVER ENDING PROBLEM  
Microorganisms, like bacteria, are one of the oldest forms of life on earth 
and have been reigned on our planet, evolving or outlasting many obstacles they 
have encountered, for more than 2 billion years [1]. While commonly classified 
phylogenetically [2], bacteria may also be categorised and described by means of 
their shape. Bacterial shape can vary from spheres (cocci) to rods (bacilli) of 
differing length and width, as well as more complex shapes, such as stars. 
 The incredible adapting mechanisms of bacteria have allowed them to 
survive still in the 21st century. Although with the introduction of antibiotics and 
vaccines the reign of bacteria was under treat, these old microorganisms have 
progressively neutralised the effectiveness of antibiotics by developing resistance. 
Nowadays, antibiotics resistance has reach a critical level and becomes a serious 
public health treat, invalidating major antimicrobial drugs that are currently used in 
the clinic [3]. 
The bacterial resistance emergency has been widely documented and has 
a huge economic impact on national health system [1]. According to the World 
Health Organisation (WHO) definition, a bacterial strain is considered resistant 
when it no longer responds to standard treatments and therefore the infection is 
difficult to treat [4]. In 2014, the WHO stated that the bacterial resistance crisis is 
becoming dire [5]. The increase of bacteria resistant strain will mean an increasing 
use of older and less effective techniques, including debridement, disinfection, 
amputation, and isolation, for controlling the infections. European Centre for 
Disease Prevention and Control (ECDC) reported that, every year, 25000 people 
die from infections caused by multi-resistant bacteria [6]. Moreover those resistant 
microorganisms cost about 1.5 billion euros in extra healthcare services and 
productivity losses per year to Europe [7]. 
A number of common multidrug resistance bacteria have been registered by 
the Centre for Disease Control and Prevention (CDC) [8]. Bacteria like 
staphylococci, enterococci, Enterobacter spp, Klebsiella pneumoniae and 
Pseudomonas spp, are commonly present in healthcare institutions [9-12] and the 
increased mortality rates in patients with bloodstream infections have been 
associated with the increased resistance of these bacteria to common antibiotics. 
Other examples of bacteria responsible for common healthcare-associated 
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infections and multidrug-resistant bacteria are Mycobacterium tuberculosis, 
Escherichia coli, Stapylococcus aureus, Enterococci spp., nontyphoidal 
Salmonella, Shigella spp. and Neisseria gonorrhoeae. Seven factors are now used 
by CDC to assess the antibiotic-resistant bacterial infections [13]: clinical impact, 
economic impact, incidence, 10-year projection of incidence, transmissibility, 
availability of effective antibiotics and barriers to prevention. 
Three main causes have been recognised as enhancer of the drug 
resistance bacteria crisis [5]: the evolutionary response to the widespread use of 
antibiotics [14]; the increase of connection between human populations which 
enhances the spreading of the pathogens; the improper and prolonged use of 
antibiotic therapies.  
 
1.1.1 RESISTANCE MECHANISM OF BACTERIA 
There are five major mechanisms used by antibiotic against bacteria [15]: 
interference with cell wall synthesis (like β-lactams), inhibition of protein synthesis 
(like macrolides and aminoglycosides), interference with nucleic acid synthesis 
(like fluoroquinolones), inhibition of metabolic pathway (like sulphonamides) and 
disruption of bacterial membrane structure (like polymixins). Adapting 
mechanisms, like activation of enzymes responsible for drug degradation, 
modifications in membrane permeability, development of multidrug efflux pumps or 
sheltering of the microorganism inside the host cells, are the sophisticated 
mechanisms of drug resistance used by bacteria in order to avoid the action 
mechanism of antibiotics [16]. 
 
MODIFICATION OF ANTIBIOTIC MOLECULES 
Chemical alteration of the antibiotic molecules is one of the resistant 
mechanisms used by both Gram-negative and Gram-positive bacteria. In order to 
reduce or eliminate the activity of the antibiotic, particular enzymes are produced 
by the bacteria itself, which are capable of introducing chemical changes to the 
antimicrobial molecule. Most of the antibiotics neutralised by these methods 
explicate their action inferring with protein synthesis [12, 17]. The most frequent 
biochemical reactions catalysed by these bacterial enzymes include acetylation, 
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phosphorylation and adenylation. Penicillin-resistant S. aureus is an example of 
bacteria who use an enzyme, β- lactamases, in order to destruct molecules of a 
specific class of antibiotic, the β- lactam [12]. Molecules of this class of antibiotic 
are inactivated through the destruction of the amide bond of the β-lactam ring, 
which inactivates the effect of the antibiotic. In order to overcome this resistant, 
new β-lactam molecules with a wider spectrum of activity and less susceptibility to 
the enzyme were manufactured, however discover of these new compounds have 
been followed by the rapid appearance of new bacterial enzymes capable of 
neutralising these molecules. 
 
DECREASED OF ANTIBIOTIC PENETRATION AND FFFLUX PUMPS 
Another resistant mechanism developed by bacteria, in particular Gram-
negative bacteria, is to prevent the antibiotic´s access to its intracellular or 
periplasmic target [11]. In this resistance mechanism the bacterial membrane, the 
porins and the efflux pumps act either as a barrier against the permeation of the 
antimicrobial drug or as a decreasing mechanism for the intra-bacterial antibiotic 
concentration, which cannot therefore exert its antimicrobial effect. 
Many common antibiotics like β-lactams, tetracyclines and some 
fluoroquinolones, are highly hydrophilic molecules which are particularly affected 
by changes in permeability of the outer membrane. These molecules use porins, 
water-filled diffusion channels present inside the bacterial membrane in order to 
cross the bacterial barrier [18]. Alterations of the porins, achieved for example by a 
shift in the type of porins expression on the surface of the bacteria, can change the 
permeability of antibiotic molecules, although this mechanism results in low-level 
resistance [19]. Different types of porin-mediated antibiotic resistance have been 
described and characterised in different Gram-negative bacteria, for example E. 
coli is able to express three major proteins (known as OmpF, OmpC and PhoE) 
which increase the resistance mechanism to cephamycins and other β-lactams 
[11]. 
Efflux pumps are other structures present inside the bacterial membrane 
which are able to limit the uptake of antibiotic inside bacteria [20]. They can affect 
the intracellular bacterial concentration of antibiotics like protein synthesis 
inhibitors, fluoroquinolones, β-lactams, carbapenems and polymyxins. Many 
  
15 
classes of efflux pumps have been discovered in both gram-negative and gram-
positive bacteria, which can be substrate-specific for a particular antibiotic or with 
broad substrate specificity. 
 
BACTERIA SHELTERING INTO THE HOST CELLS 
Invasion of the bacteria inside the host cells is a mechanism used by the so 
called intracellular bacteria in order to protect themselves from the antibiotic action 
[21-23]. Intracellular bacteria have the ability of inducing their own phagocytosis 
into cells that are normally nonphagocytic, like M-cells [24]. These types of 
bacteria are able not only to hide in the cytosol of the host cells, but also in 
endosome, nucleus, Golgi apparatus or in the endoplasmic reticulum of the 
infected cells. As most common anti-infective agents have a poor membrane 
permeability, they will not be able to reach the infection when the bacteria are 
sheltered inside the cells. Moreover, the antibiotics, which are able to permeate the 
host cells, once inside the cell, are rapidly degraded or have a concentration below 
the therapeutic levels [25]. In table 1.1, a list of the most common intracellular 
bacteria is shown. This mechanism of resistance is used by bacteria localised in 




Table 1.1 Main intracellular bacteria with the associated diseases and their localisation. The table 
was modified from Abed et al.[26] 





Salmonella spp. [28, 29] Typhoid fever Macrophages, 
enterocytes 










Yesinia pestis[32] Plague Macrophages 
E. coli[33] Diarrhoeal illness, urinary 












S. aureus [36] Pneumonia, mastitis, 
phlebitis, endocarditis, 
nosocomial infections, 






For intracellular bacteria, the success of the infection depends on the 
interaction between the bacteria and the host cells and the messages sent from 
the bacteria to the infected cells and the other way around [37]. During the 
internalisation process the bacteria play therefore an active role in the bacteria-cell 
communication. Afterwards the microorganisms can either remain in a vacuole in 
which they replicate (like Mycobacteria spp. [38] and L. pneumophila [39]), or 
escape and replicate in the cytosol (like Shigella spp. [40] and Listeria spp. [41]). 
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Two major types of induced uptake are mainly used by invasive bacteria for 
colonisation of mammalian cells [37]: a “zipper” mechanism that involves a direct 
contact between a surface bacterial protein and its surface receptor on the cell 
host membrane, that create a vacuole which engulfs the bacterium; a “trigger” 
mechanism in which a signal is sent from the bacteria to the mammalian cell, 
inducing cytoskeletal rearrangements and resulting in macropinocytosis. The first 
strategy is used by Yersinia and Listeria [41], instead the second one by 
Salmonella and Shigella [40]. 
Almost for all intracellular bacteria, membrane-bound vacuole is part of their 
invasion process, however the intracellular life of the bacteria may vary. Bacteria 
can either remain in a vacuole, in which they replicate (like Mycobacteria [38], S. 
aureus [42] and L. pneumophila [39]), or escape and replicate in the cytosol (like 
Shigella spp. [40] and Listeria spp. [41]). 
For surviving inside the vacuole the bacteria have to develop strategies for 
surviving in a hostile and changing environment, characterised by poor nutrient 
content, progressive decrease of the pH and delivery of antibacterial peptides and 
lysosomal enzymes [43]. For example some bacteria are able to develop a 
mechanism to prevent fusion of the bacteria-containing vacuole with lysosomes 
[37], which protects the niche of the pathogen inside the host cell [38]. Two major 
survival strategies are developed by bacteria, although some species, like 
Salmonella [44], may use a combination of both: bacteria develop a state of 
metabolic adaptation to the stress imposed by hostile conditions; microorganisms 
create for themselves a less hostile niche through alteration of the biogenesis and 
dynamics of their vacuole compartment, which allows their survival and growth. 
Once the intracellular infection is established and the invasive bacteria are 
able to replicate, the pathogen will damage the host cells till death causing the 
clinical symptoms of disease. For example bacteria like Pseudomonas, S. aureus, 
tetanus, diphtheria, botulism, and cholera secrete toxins which are able to kill the 
infected cells [37, 45]. Other bacteria instead are able to damage the host cells 







1.2 ENTEROPATHOGENIC BACTERIA 
Many common enteropathogenic bacteria, such as Shigella flexneri and 
Yersinia pseudotuberculosis, are capable of sheltering inside enterocytes, where, 
due to the common poor membrane permeability of anti-infective agents, they are 
difficult to reach [21-23]. These diarrhea-causing pathogens are able to resist non-
specific host defences and disrupt the intestinal epithelium [46]. Depending on 
their virulent properties [24, 47], these enteropathogenic bacteria can invade either 
the local mucosa (Shigella spp. [48]) or the local intestinal region (Yersinia spp. 
[49]) and progress to a systemic infection (Salmonella spp. [50]). 
The specific invasion strategy of a bacterium is affected by virulence 
factors, acting on the host cell membrane or from the intracellular side of 
mammalian cells. Each enteropathogenic bacterial species has a different invasion 
mechanism, which involves specific host cell-bacteria interactions; however the 
two steps common to each mechanism are the adhesion of the bacteria on the 
host membrane and the later invasion inside the cells. 
 
For example, the adhesion and invasion strategy for S. flexneri (Figure 1.1) 
starts with the exhibition to bile salt of a specific protein (IpaB) on the type III 





Figure 1.1 Shighella invasion of epithelial cells[51]. 
After exposition of the protein IpaB, the interaction between the cell surface receptor and the bacteria 
tip complex enhances the insertion of bacterial proteins, like IpaB, IpgB1, IpaA and IpaC, into the 
mammalian cell (1). A cascade of signals is then activated, causing reorganisation of the cytoskeleton, 
actin polymerisation and bacterial anchorage to the invasion site. C-terminal domain of IpaC will 
activate the Src tyrosine kinase and actin polymerisation (2). Reorganisation of the actin cytoskeleton 
(green) is also caused by injection from the bacteria of type III effectors, like IpgB1. This protein will 
activate Rac, which further amplifies actin polymerisation at invasion sites. Another bacterial protein, 
IpaA will promote the bacterial anchorage to the cytoskeleton at invasion sites and contribute to actin 
depolymerisation during the completion of the bacterial invasion process.  
Adhesion to the host cells is then likely caused by interaction between 
filopodial extensions, surface sensory organelles on the surface of M cells, and the 
head of T3SA. Afterwards activated T3SA allows the injection of effector proteins, 
like IpaA, IpaB, IpgB1, IpgB2 and IpaC, into the host cell. IpaB/C complex is able 
to form a pore structure in the host cell membrane, which is then linked to the 
T3AS in order to further inject other effector proteins [53]. The injected effector 
proteins are important not only for the pore formation but for the invasion step as 
well. Reorganisation of the actin cytoskeleton - caused by Src tyrosine kinase 
activation mediated by IpaC and by activation of Ras-related C3 botulinum toxin 
(Rac) through IpgB1 - and depolymerisation of the actin filaments - mediated by 
IpaA - allow for the invasion of the bacteria inside the host. S. flexneri is normally 
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internalised inside the host cells via micropinocytosis and, when the invasion is 
completed, the bacteria are able to disrupt the vacuole structure [51, 54, 55].  
Intracellular S. flexneri is then able to form an actin tail, which is used by the 
bacteria to move inside the cells and invade neighbouring epithelial cells. The 
intracellular bacteria will start to multiply into the cytosol and the infection will 
spread from cell to cell [56]. Once the bacteria invade and pass the M cells, they 
are able to release mediators which induce apoptosis of macrophages, B cells, 
and T cells [37]. Due to the hidden localisation, S. flexneri infections are difficult to 
treat with common antibiotics. A severe disruption of the integrity of the intestinal 
mucosa, associated with ulcers and mucosal abscesses, and a severe 
inflammation are the clinical symptoms of shigellosis [57, 58].  
 
Another interesting invasion mechanism is done by Yersinia spp. These 
bacteria have an outer membrane protein called invasin. This is a well-
characterised outer membrane invasion protein expressed on the surface of Y. 
pseudotuberculosis and Yersinia enterocolitica, which mediates an efficient entry 
of the bacteria into eukaryotic cells through interaction with β1 integrin receptors 
[59-61].  
This protein is encoded by the invasin gene of Y. pseudotuberculosis and 
consists of 986 amino acids [62]. Invasin protein has an N-terminal β-barrel 
structure, which is located within the bacterial membrane of the bacterium, and a 





Figure 1.2 Structure of the extracellular binding domain of invasin [63]. 
The structure of the C-terminal part of invasin is shown in the figure. One cellular binding domain (A) 
and four immunoglobulin-like domain (B) form extracellular part of this bacterial protein. 
 
 The last 192 amino acids of the C-terminal region of invasin have been 
found to be particularly important for receptor binding and intracellular uptake [60]. 
The extracellular terminal region is composed of 4 immunoglobulin-like domains 
and one cell-binding domain, forming an elongated, rod-like structure [65]. Dersch 
et al. were able to produce and purify such a C-terminal, cell-invasive fragment of 
invasin, referred to as InvA497, which demonstrated a conserved binding capacity 
[60]. 
In order to initiate a bacterial infection, invasin is able to bind with β1 
integrins on the apical surface of M cells located within the intestinal mucosa [66]. 
In order to invade the cells, the Yersinia bacteria need the intervention of another 
invasive protein located on its surface, YadA. Both YadA and invasin activate PI3 
kinase upon binding to β1-integrins [67, 68]. This triggers the production of short-
lived host PIs, like Akt kinase, PLC-g1 and PKC isoforms PKCa and PKCb, which 
control the recruitment and activation of different phagocytosis cellular effectors 
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[68]. These two bacterial proteins on the surface of Yersinia bacteria are therefore 
able to initiate several intracellular signals which end with the internalisation of the 
bacteria through vacuoles. After translocation through intestinal M-cells, Yersinia 
bacteria are able to move into the subepithelial dome of the Peyer's patches. In 
this dome, the immune response will be activated via dendritic cells, macrophages 
and lymphocytes, resulting in an increased intracellular and paracellular 
permeability[56]. 
After invasion of the M cells, and in order to avoid uptake into the 
phagocytic cells and death, the Yersinia is able to inject a bacterial protein which 
interferes with phagocytosis, like Yops [37]. The bacteria therefore remain 
extracellular, allowing their survival and multiplication in lymphoid tissues. 
 
1.2.1 TREATMENT FOR INTRACELLULAR BACTERIA 
For decades, intracellular enteropathogenic infections have been treated 
with anti-infective drugs. Due to the intracellular localisation of these bacteria, 
however, the number of antibiotics used and their action is limited. The antibiotic 
molecules must first overcome in the intestinal barrier and then be internalised by 
the bacteria. One of the critical challenges for these types of infections is the 
concentration of the drugs that is able to reach the pathogens within their 
intracellular compartments.  
Generally therapies against intracellular bacteria involve a combination of 
drugs administrated for a long time [69]. Due to their short half-life, these 
antibiotics need to be frequently administrated with a high dose in order to obtain 
the therapeutic effect. Therefore these therapies may develop side effects due to 
the drug’s inherent toxicity and lead to high cost. 
The preferred antibiotic therapy against enteropathogenic bacteria was 
fluoroquinolone, like ciprofloxacin. However, due to recent increased antibiotic 
resistance, macrolide, like azithromycin, are now preferentially used [70]. 
An ideal antibiotic treatment to eradicate intracellular bacteria need to have 
the following characteristics: the molecule need to be able to penetrate inside the 
host cells and gets into the infection site; the antibiotic needs to have a high 




In order to treat intracellular infections caused by enteropathogenic bacteria, 
incorporation of drug candidates into nanoparticles could be a solution. The first 
advantage of these systems is the increased of stability and shelf life of the 
antibiotic molecules encapsulated into the nanoparticle [3, 71]. Moreover with the 
administration of nanoparticles, there is a controllable and relatively uniform 
distribution into the target tissue, which leads to a reduction of the side and toxic 
effect and a reduction of the administrated dose [72-74]. 
It is demonstrated that encapsulation of antibiotics into liposomal or 
polymeric nanoparticles formulations increases the maximal tolerated dose and the 
therapeutic effect of the molecule compared with the free drug [75, 76]. Fattal et al. 
for example found an increase by 120-fold of the efficacy of ampicillin against 
Salmonella typhimurium when the antibiotic is encapsulated inside 
poly(isobutylcyanoacrylate) nanoparticles [77]. Ampicillin loaded nanoparticles 
were tested in a mice model with acute Salmonella infection. It was found that 
100% of the infected mice treated with a single dose of the nanoparticles survived, 
whereas all the untreated animals died. Polymeric nanoparticles were able to 
reach the intracellular location of the Salmonella bacteria and the released 
antibiotic was able to kill the microorganisms. Ampicillin loaded liposomes were 
also tested on the same model, however the treatment was less efficient and only 
60 % of the mice survived [78]. 
Nanoparticulate systems can also be used for the administration of both 
lipophilic antibiotic molecules, which are difficult to administrate due to solubility 
problem in water, or for hydrophilic antibiotic, which normally cannot penetrate the 
mammalian cell membrane, against intracellular bacteria [3, 74, 79, 80]. The 
difficult localisation of these bacteria can be overcome by the administration of 
antibiotic loaded nanoparticles, which are able to be internalised inside the cells 
and release the drug where the bacteria are localised. Targeting of the infection 
site can either be passive, where the distribution and uptake of the nanoparticles is 
casual, or active, where distribution and uptake can be driven by active vectoring 
[4]. 
For active target, the ligand is usually attached on the surface of the 
nanoparticles and, in accordance with the ligand-receptor binding theory [81], such 
structure is able to enhance the interactions with the cell membrane and the 
uptake of the system [4, 25, 82]. The ligand needs to be chosen depending on the 
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stability and selectivity for the target cells. For examples, different studies show 
that saccharides are the best ligand for macrophages or phagocytic cells targeting, 
due to the presence of a lectin receptors on the surface of phagocytic cells [4, 83-
86]. 
Compared with non-functionalised nanoparticles, targeted delivery of 
antimicrobial drug may increase the success rate of therapy for chronic and 
persistent infections [87]. Specific target molecules on the particles surface have 
been shown to be able to recognise the unique surface properties of the targeted 
cells [81]. Bacterial molecules or and even bacterial invasion systems have been 
explored in the recent year as new strategies for active targeting. In this respect, 
the use of bacterial proteins which naturally mediate the invasion of bacteria into 
mammalian cells has been reported as a promising means of enhancing the 
permeation of carrier systems and potentially increasing the intracellular efficacy of 
their drug loads. These functionalised systems are called as bacteriomimetic 
particles. 
For example, Salaman et al. were able to produce Salmonella-like 
nanoparticles, obtained by coupling Salmonella enteritidis flagellin or 
monnosamine, or Brucella ovis´ lipopolysaccharide loaded particle [88]. Adhesion 
of these systems on gastrointestinal mucosa of Wistar rats was tested as well as 
the immune response. It was found that only Salmonella-like nanoparticles were 
able to display a strong mucosa affinity and, after penetrating into the tissue, to 
induce a release of immunoglobulins [88]. 
Another type of bacteriomimetic system was produced by Gabor et al. using 
K99-fibriae from E.coli [89]. This system consists of mucoadhesive polyacrylic acid 
and K99-fimbriae covalently bound to this matrix system. The receptor specific 
adhesion of this bacteriomimetic system was confirmed on different types of 
epithelial cell lines, like Caco-2, SW620, SW480 and human colonocytes. 
Although the use of bacteria protein or bacterial invasion systems could be 
a solution for specific tissue targeting, a few aspects must be considered. First the 
bacterial protein must be extract and purified from the bacteria using a 
reproducible method. These bacterial factors must also be stable during the 
coupling process on the particle system and their affinity for the receptor should 
not be altered. The possible immunogenic effect caused by the presence of 
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bacterial proteins or systems on the surface of the particle must also be 
considered. 
 
In recent years, invasin and its uptake enhancer properties have been 
studied in the field of drug delivery. In particular gentamicin-loaded liposomes, 
surface functionalised with InvA497, were prepared and it was further 
demonstrated their ability to reach and kill intracellular bacteria located in various 
epithelial sub-cellular compartments [90, 91]. Similar results were found by 
Dawson et al., who prepared poly (lactic-co-glycolic acid) (PLGA) nanoparticles 
functionalised with invasin and tested their uptake in HEp-2 cells [92]. It was 
shown that this polymeric system was able to penetrate the cells with an uptake 
mechanism dependent from the invasin density on the surface. Other study with 
latex nanoparticles with surface-coupled invasin shows an epithelial absorption 
and systemic distribution of these bacteriomimetic particles in rats [93]. 
In all these studies invasin was chosen for its strong affinity for the receptor 
β1-receptor, located on different types of epithelial cells (HEp-2, Calu3), as well as 
for the possibilities of using an easy and quick coupling procedure for the 
covalently linkage with the particle.  
 
1.3 ASPHERICAL NANOPARTICLES 
Typically, nano- and microparticles have been produced with spherical 
shape. However, a large number of examples of non-spherical shapes can be 
found in natural systems, such as bacteria, virus, fungi and erythrocytes, where the 
importance of the non-spherical shape is demonstrated [94-96]. 
Recent studies have shown the possible application of aspherical particles 
in order to modify biodistribution and circulation in the blood stream or cellular 
internalisation and trafficking. Moreover application of particles with an aspherical 
shape has been studied for some field of the nanomedicine, like therapy for cancer 
or pulmonary application. 
In the following subsection, the most common preparation for aspherical 




1.3.1 PREPARATION METHODS 
New methods for the production of aspherical particles have been 
discovered or optimised, in order to study the influence of aspherical drug delivery 
systems on biological systems and processes, such as uptake, distribution and 
clearance. These preparation methods can be divided in two categories [97-99]: 
methods where the aspherical systems are produced or synthesised de-novo, also 
called bottom-up approaches; and methods that utilise already formed spherical 
particles as precursors, also known as top-down methods. 
These different methods were designed in order to produce micro- or 
nanoparticles with a specific shape and size, using either inorganic or organic 
materials. Although some progress has been made in the production of aspherical 
systems, these methods are not all suitable for large scale production, like 
industry, but are rather designed for laboratory scale-production and testing. 
 
Comparing the two different categories, bottom-up approaches could be 
readily scalable to larger production and different material can be used, however 
the particle size and uniformity is not always reproducible and only some shapes 
can be produced [97]. In contrast, top-down approaches require specific machinery 
or templates in order to create the aspherical systems. Examples of aspherical 






Figure 1.3 Examples of aspherical systems produced by different preparation methods. 
a) silica ‘worms’, scale bar 200 nm [100]; b) rod shape microparticles prepared using the template-
assisted method, scale bar 1 µm [101]; c) Trojan horse PRINT® (Particle Replication in Non-wetting 
Templates) particles loaded with doxorubicin, scale bar 5 µm [102]; d) triangular particles produced 
using a lithography approach, scale bar 300 nm [103]; e) particles prepared with microfluidics, scale 
bar 10 µm [104]; f) aspherical polymeric nanoparticles produced by a stretching method, scale bar 
200 nm. 
 
1.3.1.1 BOTTOM-UP APPROACH 
A classical bottom-up approach is the synthesis of aspherical particles from 
organic or inorganic materials, using specific preparation conditions which 
enhance the formation of the non-spherical shape. For example, crystals of 
different metals can be grown into cubes or rods [105], or even more complex 
structures like dots [106]. For the production of particles with bottom-up 
approaches different inorganic material can be used, like gold [107, 108], silver 
and silica [100, 109], however the encapsulation of drug or surface modification is 
difficult or, in some cases, even not possible. 
For the synthesis of organic aspherical systems, different polymers or self-
assembly block copolymers (like self-assembly polymer made by blocks of poly-
(ethylene oxide), poly(ethyl ethylene) and poly(perfluoropropylene oxide)) can be 
used [110]. In this case, the ratio and orientation of hydrophobic and hydrophilic 
domains as well as the particle synthesis conditions (such as temperature, solvent, 
polymer concentration) have a big influence on the shape and dimension of the 
aspherical systems [111]. It was found that for squalene-based nanoparticles for 
example, where an anticancer drug was conjugate with the lipid chain, the position 
of the squalene moiety relative to the drug determined the shape of the self-
assembly system [112]. 
Due to the limitation of the bottom-up techniques, such as the difficulties in 
the preparation of uniform batches of particle or in the encapsulation of drug or in 






1.3.1.2 TOP-DOWN APPROACHES 
Much progress has been made in recent years with respect to top-down 
approaches, and new techniques, like the template-assisted method [113-115], 
PRINT® technique (Particle Replication in Non-wetting Templates) [97, 116], 
lithography techniques [103, 117, 118], microfluidics [119-121] and stretching of 
spherical polymeric nanoparticles [122-124], have been optimised. In the next 
paragraphs, the characteristics of these preparation techniques will be explored. 
 
TEMPLATE-ASSISTED METHOD 
The template-assisted method is used to prepare rod-like or cylindrical 
particles, forcing a raw material or spherical particulate systems into a template, 
usually made with anodised aluminum oxide (AAO) and track-etched polymer 
membranes [115, 117]. The employed raw material or spherical particle systems 
are deposited inside the membrane pores using different techniques, depending 
on the filling material itself, such as electrochemical deposition, electrophoretic 
deposition or direct filling with a solution [113]. Spherical nanoparticles are usually 
directly filled inside the pores of the membrane (Figure 1.4 a) and through cross-
linking agents [125] or the use of heat [126], the spheres are bonded together in 
order to form a new system with an aspherical shape (Figure 1.4 b). Alumina 
membranes and polycarbonate track-etched membranes are the two most 
common used mold. The dimension of the nanoparticles depends on the pore size 
of the mold and by the thickness of the membrane. The newly formed aspherical 
system is then removed from the membrane pores using different methods. Due to 
the nature of the membrane, the most common used method for the dissolving the 
mold are organic solvent, like tetrahydrofuran or ethyl acetate [127]. These 
solvents, however, limited the material that can be used for the preparation of the 
aspherical nanoparticles, as these organic solvents can compromise the stability of 
the encapsulated drug and dissolve polymeric nanoparticles used for the 
preparation. Other methods, like acid solution (like phosphoric acid solution [128]) 






Figure 1.4 Schematic representation of the template-assisted method. 
a) The pores of the alumina or polycarbonate track-etched membranes are used as template and filled 
with spherical nanoparticles. b) A cross-linking agent or heat are used in order to connect the 
nanoparticles. c) The newly formed aspherical nanoparticles are then removed from the membrane 
stamp and collected. 
 
Kohler et al. were able to create rod-like microparticles by filling a 
polycarbonate membrane with spherical silica nanoparticles, and crosslinking 
these nanoparticles with a polyelectrolyte layer-by-layer coating. The 
interconnection of the spherical nanoparticulates resulted in a new system with an 
elongated shape [125]. Further studies have also demonstrated the possibility of 
using these aspherical microparticles for gene delivery and macrophage targeting 
[101, 129]. A different approach was used by Yin et al., where polystyrene beads 
were used to fill the membrane and interconnection between the nanoparticles is 
formed using via thermal treatment at a temperature slightly higher than the glass 
transition temperature [126]. 
Protein nanotubes, made with glucose oxidase protein, have also been 
prepared using AAO membranes as templates, and glutaraldehyde as a cross-
linking agent to hold the protein layers together [128]. Layers of protein were 
infiltrated through the pores of the AAO membrane and a phosphoric acid solution 
was used in order to dissolve the mold. It was demonstrated that not only the 
activity of glucose oxidase was preserved after the treatment with the acid solution, 
but also increased with the number of layers of glucose oxidase. 
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While the template-assisted method appears to result in a reproducible 
particle shape, a considerable limitation of this method is that only rod-like or 
microtubes particles can be produced. Moreover, the ability of the spherical 
precursor systems and eventually also any encapsulated drug to resist the harsh 
conditions required to dissolve the membrane and liberate the produced particles 
is a problem of this technique. Drug can either be encapsulated into the spherical 
nanoparticle or mixed with the linking agent that interconnects the spherical 
systems. In both cases, if the drug is able to keep its activity after dissolving the 
membrane, the kinetic released would be probably slow and depends on the layers 
of linking agent used during the preparation process. 
 
LITHOGRAPHY METHOD AND PRINT® 
In the late 90´s Whitesides et al. developed a new high-resolution and low-
cost method for the fabrication of differently-shaped nanoparticles, the 
nanoimprinting lithography method [130]. Using an elastomeric mold produced 
using an elastomeric or fluorocarbon-based silane rigid template, micrometer and 
nanometer sized particles of various shape morphologies, like worm shape 
nanoparticles or nanorods, were able to be stamped. In order to produce these 
particles, a polymeric solution (like a polymer-coated silica or quartz substrate or 
polyethylene glycol (PEG) derivatives of different molecular weight) is forced into 
the mold, and through heat or ultraviolet (UV) stimulation, particles are formed with 
the exact shape and dimensions of the mold. Following this finding by Whitesides 
et al., lithography was optimised in order to produce nanoparticles with different 
shape [103, 131, 132]. 
Lithography allows not only for the preparation of empty nanoparticles, but 
also for drug loading and particle surface functionalisation [103]. Roy et al. have 
used the lithography technique, to prepare cubes, triangular and pentagonal 
cylinders particles loaded with protein, antibodies or nucleic acids [103]. They were 
able for example to encapsulate streptavidin-CY5 within nanoimprinted PEG 
diacrylates particles by mixing the protein with the polymeric solution before the 
formation of the particles. 
Two of the major problems regarding this technique are the excess of 
material during the formation of the particles and the need to detach the formed 
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systems from the mold. To solve the latter problem, many groups cover the 
surface of the mold with an extra layer of a polymer which, unlike the particle 
polymer component, is then dissolved with acetone [132] or with water [133].  
 
A considerable improvement in the preparation of aspherical nanoparticles 
was achieved with the introduction of the previously mentioned PRINT® technique. 
The non-wetting properties of a perfluoropolyether (PFPE) mould are used in this 
technique in order to form particle systems with the shape of the template cavity. 
With this technique the physical properties of produced particles (such as size, 
shape, homogeneity) can be controlled, and surface functionalisation and drug 
encapsulation may also be achieved [116]. Another advantage of this technique is 
the possibility for encapsulation of DNA, protein or small molecules inside 
nanoparticles [134, 135]. 
Like in the above mentioned lithography methods, in the PRINT® process a 
liquid precursor of the nanoparticles, like monomers, is forced into the mold and 
through a solidification process, using techniques such as lyophilisation, solvent 
evaporation, thermal curing/annealing or photo-chemical cross-linking [135], the 
polymer chains and the particles are formed (Figure 1.5). Comparing with 
lithography however, the non-wetting and non-swelling properties of the mold allow 
for the production of single and not-interconnected particles, also on the 






Figure 1.5 Differences between traditional imprint lithography and PRINT® technology. 
With the PRINT® approach, the liquid, raw substance is forced into the cavity of a non-wetting PFPE 
mold, resulting in the formation of isolated particles. Figure reproduced with permission from 
ref.[116]. 
 
The shape of PRINT®-formed particles depends on the morphology of the 
mold cavity. Gratton et al. were able to form poly(ethylene glycol) hydrogel 
particles with different shapes (cubic and cylindrical) and of different sizes (micro- 
and nanoparticles) by changing the mold cavity [136]. Petros et al. were able to 
produce PRINT® particles also with a cubic shape, and with encapsulated 
doxorubicin [102]. This system was tested on cancer cells (HeLa cells) where it 
was demonstrated that drug release was triggered by the reducing environment of 
the tumor. This innovative technique can also be used to combine common and 
biodegradable polymers like PLGA with antigens from the influenza virus (HA 
antigen) in order to produce a vaccine delivery system with an aspherical shape 
[137]. In comparison with PLGA-based nanoparticles produced with other 
techniques, such as solvent evaporation method[138], the extent of HA on the 
particle surface was greater with the PRINT® produced formulation compared with 
other spherical formulation. Due to the high concentration on the surface of the 
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PRINT® prepared nanoparticles, PLGA-HA functionalised system was able to 
generate responses to influenza hemagglutinin in murine models. 
For both PRINT® and lithography methods, a big problem is the purification 
step, used to remove the fragment of particles after the mold is removed. Moreover 
the material and degradation of the drug during the preparation process can limit 
the use these techniques. These disadvantages are however mitigated for 
PRINT® by the high reproducibility and flexibility, and by the continuous progress 
in the mold manufacturing resulting in progressively decreasing costs [135]. 
 
MICROFLUIDICS 
Another technique that allows the preparation of particles with a non-
spherical shape is that of microfluidics. A commonly microfluidics device setup is 
equipped with digital micromirror devices and two perpendicular microchannels, 
forming a T-junction structure [139]. Inside of these two channels a solution of the 
polymer precursors is passing through. The position of the two channels and the 
minute amounts of liquid that flow through them allow the creation of 
monodisperse emulsion droplets, with a shape dependent on the channel 
geometry [140]. Through the UV light projected by the micromirror devices on the 
microchannel, polymerisation process is initiated and particles with a precise 
shape and dimension are generated. Different types of microfluidics devices have 
been optimised for the formation of aspherical particles, employing microchannel 
of different architecture [119, 141], flow focusing channels [142], or incorporating 
co-flow based systems [143]. Moreover, other techniques as alternative to the UV 
polymerisation can be used depending on the material in order to create the 
nanoparticles, like solvent evaporation, thermal polymerisation or chemical 
polymerisation reactions [97]. 
In general, for microfluidics approaches, the shape and size of the particles 
produced depends on the channel geometry. Mainly rods, ellipsoids, discs or 
cylinders [144-146] have been produced to date, however as a result of the 
optimisation of channel design, particles with more complex shapes [147] (such as 
flat polygonal or curved structures [104], core-shell particle [148] or bullet shapes 
[149]) have also been reported. 
  
34 
Although optimisation of microfluidics devices has allowed the creation of 
complex systems, constraints in terms of microchannel dimension, and therefore of 
produced particle systems, there are some limitations to this technique. Particles 
produced using microfluidics approaches generally have a size between 10 and 
100 µm [120, 121, 150]. Difficulties in scale up and the high volume of liquid 
required are other two disadvantages of the microfluidics approach. 
 
STRETCHING METHOD 
A simple and flexible lab-scale method for the production of aspherical 
micro- and nanoparticles has recently been developed and optimised – the film 
stretching method. This approach was firstly developed by Ho et al. [151] and 
optimised by Mitragotri et al. [123]. The film stretching method allows for the 
preparation of polymeric aspherical micro- and nanocarriers of different shapes 
using a custom-made stretching machine [151]. In this setup, spherical polymeric 
particle precursors are dispersed within a polyvinyl alcohol (PVA) and glycerol film, 
which is then mounted onto the stretching apparatus. The entire setup is then 
immersed in an oil bath at high temperature or in an organic solvent [123], and the 
film is stretched by the application of a tensile force. Stretching of the film results in 
a change in shape of the contained particles. The particle systems are then fixed 
into their new shape by extracting the solvent or reducing the temperature as 
appropriate. Depending on the extent to which the film is stretched and in which 
dimensions, different particle shapes can be obtained, including rod-shaped or 
elliptical nanoparticles (major dimension between 0.35 and 2.5 µm in length and a 
minor dimension between 0.2 and 2 µm) as well as disk systems [152]. 
For the film stretching method, spherical particles made by different 
material, like polystyrene nanoparticles or spherical systems made with shape-
memory polymers, were used and stretched in order to obtain aspherical systems 
[98, 123, 153-157]. Examples of the application of this technique was done by 
Mitragotri et al., who were able to produce polystyrene cylindrical nanoparticles 
coated with an antibody in order to target the vascular endothelium [158] and also 
trastuzumab coated polystyrene nanorods and nanodisks to check shape influence 
on growth inhibition of HER2+ breast cancer cells [159]. 
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Although with the film stretching methods, micro- and nanoparticles with a 
complex shape can be easily prepared, the preparation condition (heat or organic 
solvent) to which the drug or protein should be exposed, it´s a limitation. 
 
1.3.2 INFLUENCE OF PARTICLE SHAPE ON BIOLOGICAL 
PROCESSES 
The importance of the shape of particles in biological interactions is clearly 
important, starting with the shape variation of bacteria themselves [94-96]. In the 
recent years the scientist community started to study this correlation and recent 
publications reported the influence of particle shape and design on circulation time 
and biodistribution and on the later interaction with cells [99, 160]. Correlation 
between particle shape and the efficacy of the treatment have also been studied 
for different types of disease like cancer. 
 
INFLUENCE OF PARTICLES SHAPE ON BLOOD CIRCULATION AND 
IN VIVO BIODISTRIBUTION 
The geometry of the particle systems plays an important role in the blood 
circulation and in vivo biodistribution. 
Decuzzi et al. have demonstrated the difference between the trajectories in 
the flow channel, which simulate the bood vessel, of discoidal and spherical 
particles, due to the difference in particle shape [161, 162]. The forces governing 
the trajectory and movement of particles in the blood stream (such as van der 
Waals interactions, electrical double layers, steric interactions, and solvation), 
contribute to a different extent depending on the particle geometry. Other groups 
have tried to compare blood levels of aspherical systems with their spherical 
counterparts, concluding that the circulation time was increased by the asphericity 
of the particles [163-166]. 
Additionally, the group of Discher observed a longer circulation time of self-
assembled filomicelles as compared to a spherical control [167, 168]. Surprisingly, 
the length of these long circulating filomicelles (approximately 8 μm) is equivalent 
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to the diameter of red blood cells. The increased circulation time for this elongated 
system was also seen to correlate to an improvement of efficacy, when the 
filomicelles were loaded with paclitaxel and tested in mice against tumor. When 
administered to tumor-bearing mice, accumulation of the particles inside the tumor 
was registered and as a consequence a reduction of the tumor size was observed. 
A different approach was used by Chambers et al., where the in vivo 
circulation lifetime of polystyrene disks coated with antibodies was prolonged by 
attaching the systems at the surface of red blood cells [169]. This new method was 
called “cellular-hitchhiking” [170]. 
Another group, Arnida et al., reported for gold nanorods a longer circulation 
time in blood, associated with a less distribution into the liver and higher 
accumulation in mice with orthotopic ovarian tumors, compared with their spherical 
counterparts [164]. However, after 2 hours the uptake in liver of nanorods with the 
lower aspect ratio significantly increased comparing with more elongated rod. This 
indicates an influence of both geometry and size on the rate of organ dependent 
uptake [171]. 
 
Studies have been also conducted on the influence of the morphology of the 
particulate systems on the distribution and targeting of specific organs. 
A biodistribution study in tumor-bearing mice has shown preferential 
accumulation of discoidal silica particles in the lungs, heart and spleen tissue 
compared to spherical, quasi-hemispherical and cylindrical particles of similar 
volumes [161]. 
The possibility of using aspherical systems for targeting of specific organs 
has been explored in recent years. Muro et al. demonstrated that elliptical disks 
coated with an intercellular adhesion molecule (ICAM-1) not only displayed a 
longer circulation time in vivo, but also an accumulation in the endothelial cells of 
lungs [172]. 
Interesting results were found by Gratton et al. regarding the different 
biodistribution of cuboid and rod-like nanoparticles. Biodistribution study shows 
that cylindrical systems were distributed mainly to the liver and the spleen when 




Overall, these promising results create the possibility to use the geometry of 
drug loaded particles for prolonging the circulation time and targeting specific 
organs or tissues. 
 
INFLUENCE OF PARTICLES SHAPE ON CELLULAR UPTAKE INTO 
PHAGOCYTIC CELLS 
In terms of cellular uptake, the effect of particle shape on cellular 
internalisation processes has also been a subject of recent research focus. 
A first in-depth study into the mechanism of uptake of particles with different 
geometries was conducted by Herd et al. [100]. Silica nanoparticles with different 
shapes (worm-like, cylindrical and spherical) were produced and particle 
internalisation was studied on non-phagocytic cells (primary and immortalised 
epithelial cells). In order to study the specific uptake mechanism, chemical 
inhibitors of endocytosis were also used. Spherical particles were observed to be 
mostly internalised through clathrin-mediated endocytosis by phagocytic cells, 
whereas for elongated particles (worm and cylindrical), macropinocytosis or 
phagocytic mechanisms were the preferential route of uptake. Interestingly, Herd 
et al. also concluded that the phenotype of the cells plays an important role on the 
transport mechanism, as a variation of the uptake of both elongated and spherical 
particles was registered between cells of the same type but with a different 
phenotype. 
Other studies conducted by Agarwal et al. hypothesised that three factors 
play an important role in the uptake mechanism of aspherical particles: adhesion 
forces between the particle surface and cell membranes; the energy required for 
cell membrane deformation to occur around the particle; and the extent of 
sedimentation of particles on the surface of cells [174]. 
 
Many studies have been conducted on the cellular internalisation of 
aspherical systems in phagocytic cells like macrophages [98, 153, 175, 176]. 
Uptake of aspherical nanoparticles (oblate ellipsoids, prolate ellipsoids, elliptical 
disks, rectangular disks and so-called ‘UFOs’) into such cells has been observed 
to be significantly inhibited in comparison with the spherical control, to an extent 
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dependent on the specific shape itself [176]. Champion et al. were able to 
demonstrate that the particle shape and its orientation relative to a macrophage 
cell surface are the major factors influencing the internalisation process [152, 176], 
and that elongated nanoparticles with a high aspect ratio (such as worm or rod-
shaped particles) were internalised to a lesser extent by alveolar rat macrophages 
compared with the spherical control [177]. The possible orientation of the spherical 
and elongated systems hypothesised by Champion et al. is shown in figure 1.6. 
 
 
Figure 1.6 Uptake of particles into macrophages depending on the shape and orientation. 
The possible orientation of both spherical and elongated particles into macrophages is shown. Due to 
their shape and the possibilities to have only one orientation, spherical systems can always be 
internalised. However for the elongated formulation, only the particles with the right orientation on 
the cell surface can be internalised.  
 
A further inhibition for the uptake into macrophages was seen for elongated 
PEGylated polymeric or gold nanoparticles [153, 164], indicating that a 
combination of shape with other nanoparticle characteristics, like the material of 
the particle, can modulate the uptake. 
Uptake of particulate systems into macrophages was seen also to be 
influenced not only by the geometry, but also by the size. Arnida et al. reported an 
increase after 2 hours of the uptake into liver of nanorods with the lower aspect 




INFLUENCE OF PARTICLES SHAPE ON CELLULAR UPTAKE INTO 
NON-PHAGOCYTIC CELLS 
The influence of the shape on uptake by non-phagocytic cells has also been 
studied. 
Qiu et al. were able to demonstrate a reduction of uptake of gold nanorods 
in a human breast adenocarcinoma cell line [178]. The influence of cell penetrating 
peptides on the uptake of cylindrical nanoparticles has also been studied. The 
effect of cell penetrating peptide was not registered for cylindrical nanostructures, 
however a slower escape from the cells, in order to target intracellular site, was 
also measured comparing with the spherical control [179]. 
 
Interesting results were found by Gratton et al. regarding the different 
uptake of aspherical particle by epithelial cells [136, 180]. Cuboid and rod-like 
nanoparticles, produced with the PRINT® approach, were observed to be 
internalised differently by HeLa cells. In particular, rod-like particles were 
internalised faster into HeLa cells than the cuboid, probably due to the larger 
surface area of these particles, which allows for more interaction between the 
particles and the cell membrane. The kinetics of particle uptake into Hela cells 
were also registered as being dependent on particle shape, volume, aspect ratio 
and size. 
Hinde et al. have also studied the advantages of nanoparticles with high 
aspect ratios, such as worms and rods, for delivery of doxorubicin into the nuclei of 
epithelial breast cancer cells, demonstrating the impact of various nanocarrier 
shapes on anticancer formulations [181]. 
A recent study from Dong et al. showed the influence of particle geometry 
on gastrointestinal transit and absorption, demonstrating that nanorods have a 
longer retention time in the gastrointestinal track and penetrate better into space of 







OTHER INFLUENCES OF THE PARTICLE SHAPE 
The shape of particulate delivery systems not only impacts on the 
mechanism and degree of cellular uptake, but also may have differential effects on 
other cellular aspects such as cell viability, early apoptosis, adhesion, migration 
and cytoskeleton formation [183]. Huang et al. discovered that mesoporous silica 
nanoparticles with a high degree of asphericity can affect cellular functions more 
than particles with a smaller aspect ratio [183]. 
A recent study from Cooley et al. have done a systematic studies that 
integrate various particle of different shape (spherical, oblate, prolate, rod) and 
size (micro and nano scale) to explore their wall-localization behaviour in the blood 
flow [184]. It was found that the amount of red blood cells in the flow have a great 
influence on the particle localisation in the blood vessels and that aspherical 
nanoparticle might be more favourable for in vivo vascular delivery compared to 
the spherical control. 
 
1.3.3 ASPHERICAL FUNCTIONALISED PARTICLES 
Although uptake or biodistribution studies on nanoparticles with complex 
shape have been conducted, a particular interest was given to the uptake of 
systems with a high aspect ratio (like cylinder, worm-like shape and ellipsoid). The 
previously descried results show the advantage of elongated particles over their 
spherical counterparts in terms of blood circulation, biodistribution to specific site 
and passive cellular uptake thanks to the particular geometry. This positive effect 
however needs to be further studied and as well the possibility of target moieties to 
increase the uptake specificity needs to be explored. The large surface area of 
aspherical systems could be used as scaffold for targeting moieties, increasing the 
available area between the carrier systems and the target and also the number of 
target moieties. In figure 1.7 a schematic representation of the possible interaction 
between spherical and aspherical nanoparticles functionalised on the surface with 





Figure 1.7 Interaction of particles with different shape and with target moieties with the cells. 
Spherical and aspherical particles with targeting moieties on the surface are represented. Due to the 
larger surface area of the aspherical systems, the available area between the carrier systems and the 
target is higher compared with the spherical particle. This can make the interaction between the 
aspherical formulation and the cells more favourable. 
 
Park et al. conduced a systematic study regarding the influence of shape 
and surface properties on targeting of mouse xenograft tumors, using iron oxide 
nanoparticles as a model system [185]. In this study, two different types of tumor-
homing peptides were coated on the surface of nanoworms and nanosphere. It 
was found that the elongated particles have a more efficient targeting capacity 
comparing with the nanosphere due to the multivalent interactions between the 
specific moieties on the particle surface and the target cells. Other studies show 
that biotinylated worm micelles, produced with poly(ethylene glycol)-based diblock 
copolymer, can bind to biotin-receptors of smooth muscle cells [186]. Using 
another approach, rod-like nanomicelles with a bioactive peptide on the surface 
and loaded with doxorubicin were synthesised and a specific tumor binding as well 
as target therapeutic effect was observed in vivo [187]. 
The large surface of worm-like structure seems therefore to have a positive 
effect on the targeting properties of the system. That, combined with the enhanced 
circulation that was mention before, could have a great influence on the efficacy of 
drug-loaded worm particle. 
 
Rod shape or cylindrical particles were also used for exploring the potential 
of shape combined with specific target moieties. 
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Using the previously described “cellular-hitchhiking”, Anselmo et al. were 
able to combine the advantages of rod shape on pulmonary delivery with the 
increased circulation time. This was accomplishes by antibodies mediated 
attachment of nanoparticles to the surface of red blood cells [170]. Surface of the 
rod nanoparticles was therefore coated with antibodies anti-ICAM-1 and a 
reduction of liver and spleen uptake was observed in favour of an increased 
accumulation in lung endothelium.  
Initial studies looking at the influence of surface functionalised cylindrical 
particles on uptake by non-phagocytic epithelial cells have shown that aspherical 
nanoparticles surface-functionalised with biotin had an enhanced uptake in human 
enterocytes [188] and that trastuzumab-coated nanorods had a higher uptake in 
breast cancer cell lines than spherical or disk-shaped nanoparticles [159]. Another 
study has shown the benefits of elongated particles with surface-adsorbed 
antibody or protein in targeting the endothelium [158], further highlighting the 
possibility of studying aspherical systems for delivery of chemotherapeutics. 
It seems therefore clear the potential as drug delivery system of aspherical 
system with specific target moieties on the surface. Future studies should be 
oriented on exploring particles with specific target systems on the surface, like 
bacterial protein or viruses, and their possible application as drug delivery system. 
Moreover, the binding of the functionalised particles with their target should be 
optimised in function of the optimal number of ligand and considering the force 
necessary to internalise the targeted nanoparticles inside the cell [171]. 
 
1.4 AIM 
The importance of bacterial invasion factors for bacteria itself is well studied 
and known. Proteins like invasin are used by bacteria to elegantly penetrate inside 
host cells, where they can hide from antibiotics and natural body defences. 
Moreover recent studies have shown the possibility of employing bacterial proteins 
to enhance the cellular uptake of particles. Although the importance of bacterial 
proteins for the invasion bacterial process is known, other characteristics of the 
bacteria might influence the internalisation process, including the shape of the 
microorganism. As discussed so far, the value of the shape is recognised in 
nature, as demonstrated in structures ranging from intracellular organelles to 
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bacteria, although the real implication behind each shape still remains to be fully 
elucidated. It was largely demonstrated that shape is an important parameter also 
for a particulate system [98, 117]. The potential as drug delivery system of 
bacteriomimetic particles, with both bacterial-like shape and bacterial protein on 
the surface, against different type of disease, like intracellular infection, still 
remains to be fully explored. 
The objectives of this study are related with this last question: what is the 
potential in drug delivery of a bacteriomimetic system with an aspherical shape 
and InvA497 protein conjugated on the surface? The following work was therefore 
focused on investigating the influence of shape on the physico-chemical 
characteristics of bacteriomimetic systems, using InvA497-functionalised polymeric 
nanoparticles with spherical and aspherical morphology, and on evaluating the 
potential of both spherical and aspherical drug-loaded systems for accessing and 
killing intracellular bacteria. 
 
In order to address this question the objectives of thesis were: 
 preparation of aspherical nanoparticles made with PLGA and the 
characterisation of the system; 
 conjugation of InvA497 on the surface of both aspherical and 
spherical nanoparticles and characterisation of the systems; 
 evaluation of the cytotoxicity and uptake of aspherical and spherical 
nanoparticles on HEp-2 cells in order to investigate the influence of 
shape on internalisation of bacteriomimetic system; 
 incorporation of an antibiotic inside the bacteriomimetic nanoparticles 
and evaluation of the efficacy of the resulting system against 
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Numerous types of nanoparticle formulations have been studied to date for 
pharmaceutical and medical applications, and have been extensively employed 
more specifically as drug delivery systems. The importance of the material used for 
nanoparticle preparation (e.g. polymeric, lipidic, organic/inorganic) is widely 
recognised, as this influences particle characteristics such as size, surface 
chemistry and mechanical properties [117, 122, 189]. However, due to the fact that 
typically the shape of nanoparticulate delivery systems is spherical, the true impact 
of another important parameter has largely been underestimated to date: the 
shape of nanoparticles [160, 190-192].  
We can find numerous examples of the importance of non-spherical 
colloidal structures in biological systems, from blood cells to viruses and bacteria 
[94, 95]. Recent studies have shown the possibility of using non-spherical particle 
for altering biodistribution and circulation in the blood stream [161, 184] or 
influencing the interaction of the carrier with its target [152, 175-177]. 
Recognition of the importance and applications of non-spherical drug 
delivery systems has increased in recent years; as a result, significant progress 
has been made in the development of new methods for preparing non-spherical 
particulate carriers, all of which focus on simple but efficient and reproducible 
preparation method. As described in detail in the previous chapter, these include 
chemical synthesis approaches [97], template-assisted methods [125, 193, 194], 
PRINT® technology [97, 116], lithography techniques [103, 117], stretching of 
spherical polymeric particles [122-124] and other approaches involving the 
fabrication of carbon nanotubes and aspherical structures composed of silica 
derivatives [122, 195]. 
In the present work, the film stretching method, developed by Ho et al. [151] 
and Mitragotri et al. [123], was employed. This method allows for the preparation of 
polymeric carrier systems of different shapes using a custom-made stretching 
machine [151]. In this setup, spherical particles are first dispersed in a PVA and 
glycerol film, which is then mounted onto the stretching apparatus (see below). 
The entire apparatus is then immersed in an oil bath at high temperature, or in an 
organic solvent [123], and the film, together with its contained particles, is 
stretched by the application of a tensile force. Depending on the extent to which 
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the film is stretched and in which dimensions, different shapes of particles can be 
obtained - this includes rod-shaped or elliptical particles with a major axis length of 
0.35-2.5 µm, and a minor axis of 0.2-2 µm [152]. This method has been used 
previously to prepare aspherical nanoparticles made of PLGA [153] or polystyrene 
[158, 175, 177] as well as particles consisting of more complex polymers [154]. 
Before being selected for use in the current work, the advantages and 
disadvantages of the film stretching method as compared with other methods 
described in literature were first evaluated, with particular respect to the size of the 
aspherical nanoparticles produced. Although this method exposes particles and 
any loaded drug to harsh conditions during the stretching process, the flexibility in 
size, in the nano range, and shape of produced particles, the low production costs 
and the possibility of using different polymers, represent the advantages of this 
technique.  
Although the film stretching method is quite well described in literature, the 
characterisation of the stretched aspherical nanoparticles remains to be fully 
explored. Mathaes et al. [124] showed that techniques like flow cytometry and Vi-
Cell XR Coulter Counter could be used for the characterisation of aspherical 
microparticles, however for aspherical nanoparticles only two techniques 
(asymmetric flow field flow fractionation (AF4) and dynamic light scattering (DLS)) 
are mentioned without a deep discussion.  
The following work focuses on the development and optimisation of the 
preparation procedure for producing aspherical PLGA nanoparticles from spherical 
precursors. In particular parameters like the influence of the thickness of the film, 
in which the spherical nanoparticles were immobilised for stretching, on the size 
and shape of the final produced aspherical nanoparticles was examined. Size and 
morphological analysis of the aspherical nanoparticles were conducted using 
techniques including scanning electron microscopy (SEM), DLS and AF4, in order 
to determine the most suitable method for the analysis of aspherical nanoparticles 





2.2 MATERIALS AND METHODS 
2.2.1 MATERIALS 
For the nanoparticle preparation, PLGA (Resomer RG 503 H, lactic/glycolic 
acid 50/50 wt/wt; MW 40 300 Da; inherent viscosity 0.41 dl/g; from Evonik 
Industries AG, Darmstadt, Germany), PVA (Mowiol® 4–88, Kuraray Specialties 
Europe GmbH, Frankfurt, Germany), glycerol and mineral oil (Sigma-Aldrich, 
Steinheim, Germany) were used. Trehalose, employed as a cryoprotectant for 
freeze drying, was sourced from Sigma-Aldrich (Sigma-Aldrich, Steinheim, 
Germany). For the size analysis sodium dodecyl sulfate (SDS, Sigma-Aldrich, 
Steinheim, Germany) was used. All the other solvents and chemicals used were of 
at least analytical grade, and distilled de-ionised water with conductivity of less 
than 18.2 MΩ/cm at 25 °C was employed. 
 
2.2.2 PREPARATION OF SPHERICAL NANOPARTICLES 
Spherical PLGA nanoparticles were prepared using the double emulsion 
method [196, 197]. Briefly, PLGA was first dissolved in 2 ml ethyl acetate (EtAch) 
to give a 20 mg/ml solution. A 400 µl quantity of water was then added drop-wise 
to the PLGA/EtAch solution, with simultaneous sonication at 12 W for 30 s (Digital 
sonifier 450, Branson Ultrasonic Corporation, Danbury, USA), in order to create 
the first water-in-oil (w/o) emulsion. The w/o emulsion was then poured into 4 ml of 
2% (w/v) PVA solution, and the two phases were sonicated again (12 W for 30 
seconds) to create a w/o/w double emulsion. After adding 15 ml of water, the 
formed double emulsion was left to stir overnight to allow for solvent evaporation. 
Following overnight stirring, the PVA excess was purified from the nanoparticle 
dispersion by centrifugation (10 000 g for 12 minutes at 12 °C). Nanoparticle 
suspensions were stored at 4 °C for maximum 1 week before further use, or were 
freeze dried (Alpha 2-4 LSC, Christ, Osterode am Harz, Germany) with 0.31 mg/ml 





2.2.3 PREPARATION OF ASPHERICAL NANOPARTICLES 
Aspherical nanoparticles were prepared in accordance with the film 
stretching method previously described by Ho et al. [151] and Champion et al. 
[123]. Briefly, 0.1% (w/v) of spherical nanoparticles prepared as described above 
was mixed with a solution of 10% PVA and 2% glycerol (v/v), and the resulting 
dispersion was dried overnight in a mould in order to create a flat, dry film. The film 
was then cut into rectangular sections (2x3 cm), each of which in turn were 
immobilised in an in-house fabricated stretching machine, and stretched after 
immersion in oil and heating (Figure 2.1). The film thickness was measured with a 
surface testing instrument MiniTest 3100 (ElektroPhysik Dr Steingroever GmbH & 
Co. KG, Cologne, Germany). The metal structure of the machine is composed of 
two main parts (Figure 2.1a): the upper part, consisting of a rotating screw and a 
metal cable, and the lower part, consisting of a moveable clamp together with a 
base-mounted fixed clamp. Film sections are immobilised between the moveable 
and fixed clamps, as shown in Figure 2.1b. The operator then applies a 
mechanical force by turning the rotating screw. Transfer of this force down the 
metal cable results in upward movement of the moveable clamp, and stretching of 






Figure 2.1 Schematic picture of the stretching machine. 
a) important parts (fixed and movable clamp for the particle containing film, rotatable screw and the 
metal cable) of the machine are shown; b) through the rotation of the screw and the movement of the 
upper clamp, the film is stretched. 
 
In the current work, following mounting of a film section, the stretching 
machine was immersed in mineral oil at 54 °C and allowed to equilibrate for 30 s. 
The rotating screw was then turned at a constant rate over a period of 90 s until 
the film was elongated to twice its original length. Two small stops on the machine 
sides allowed the operator to stop at the stretching endpoint. Through the applied 
thermomechanical stress, the shape of spherical nanoparticles is transformed into 
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an ellipsoid (Figure 2.2). The elongation entity was adjusted so that the major side 
of the rectangular section of the film was elongated to twice its original length. This 
procedure was repeated in order to stretch all film sections. 
 
Figure 2.2 Schematic representation of the aspherical nanoparticle preparation procedure. 
A thermomechanical stress is applied to the spherical PLGA nanoparticles immobilised in the PVA 
film, in order to recover nanoparticles with an aspherical shape. 
 
Following stretching, film sections were collected, allowed to cool, and 
washed with isopropanol to remove excess oil. Films were then dissolved in water 
to release the stretched nanoparticles, which were purified using multiple cycles of 
high speed centrifugation (20 min, 16 000 g, 12 °C) followed by 5-6 cycles of 
centrifugation (10 min, 1 179 g, 4 °C) with Centrisart tubes with a 300 kDa 
molecular weight cut off (MWCO) membrane (Sartorius, Göttingen, Germany). 
Aliquots of purified aspherical nanoparticles (1 ml volume) were stored at 4 °C until 
further characterisation. 
 
2.2.4 IMAGING OF NANOPARTICLES 
The morphology of both spherical and aspherical nanoparticles was 
characterised using SEM (Zeiss EVO HD 15, Carl Zeiss AG, Oberkochen, 
Germany) at an accelerating voltage of 5 kV. Samples were diluted and after 
drying overnight sputter coated (Quorum Q150R ES, Quorum Technologies Ltd, 





2.2.5 ANALYSIS OF SEM PICTURES 
For aspherical nanoparticles, SEM images were then used to calculate 
common shape descriptors, such as major and minor axis length, aspect ratio 
(AR), Feret´s diameter and minor Feret´s diameter (Figure 2.3) using ImageJ 
software (Fiji). 
Following fitting of aspherical nanoparticles as ellipsoid or spheroid 
structure, the major and minor particle axes were measured as the distances a-b 
and c-d respectively (Figure 2.3a). The AR of aspherical nanoparticles was 
calculated as the ratio between the major and the minor axis length. In addition, 
the Feret’s diameter and minor Feret’s diameter were calculated for aspherical 
nanoparticles. The Feret’s diameter is defined as the distance between two parallel 
tangents of the particle at an arbitrary angle, also known as the maximum caliper 
(Figure 2.3b). The minimum caliper is defined as the minor Feret´s diameter. 
                    
Figure 2.3 Schematic representations of the shape descriptors used to characterise aspherical 
nanoparticles . 
a) when the shape of nanoparticle was fitted as ellipsoid, major (a-b line) and minor (c-d line) axis 
was measured; b) Feret´s diameter (a-b line) and minor Feret´s diameter (c-d line) were also 
measured.. 
 
Using ImageJ software the major and minor axis distribution were found and 
the D10, D50 and D90 were extrapolated from the cumulative intensity. The 
cumulative intensity of the major or minor axis was calculated expressing the size 
intensity as percentage. D10, D50 and D90 parameters are defined as the 
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diameter value below which 10% (for D10), 50% (for D50) or 90% (for D90) of the 
particle population lies. 
 
2.2.6 DYNAMIC LIGHT SCATTERING 
Size and polydispersity index (PDI) of spherical and aspherical nanoparticle 
dispersions was performed by DLS using a Zetasizer Nano (Malvern Instruments 
Ltd, Worcestershire, United Kingdom). 
 
2.2.7 ASYMMETRIC FLOW FIELD FLOW FRACTIONATION 
A Wyatt Eclipse AF4 system (Wyatt Technology, Dernbach Germany), 
combined with an UltiMate® 3000 system (Thermo Fisher Scientific Inc., Waltham, 
Massachusetts, USA) equipped with UV detection, a Wyatt Down Eos multi-angle 
laser light scattering (MALLS) detector (Wyatt Technology, Dernbach Germany) 
and a Wyatt Quasi-Elastic-Light-Scattering (QELS) detector (Wyatt Technology, 
Dernbach Germany), was used. For the analysis of aspherical nanoparticles, the 
large separation channel was equipped with a 30 kDa cut-off regenerated cellulose 
membrane. A 500 µl volume of aspherical PLGA nanoparticles was injected. The 
focusing period was 7 min with an applied focus flow of 1 ml/min. The detector flow 
was set to 0.2 ml/min in order to have a laminar flow of the mobile phase (0.5% 
SDS in water with pH adjusted to 9.5). This flow creates a parabolic flow profile of 
the injected nanoparticles, with a faster stream in the middle of the channel as 
compared with near the channel walls. A cross flow was kept constant at 0.11 
ml/min in order to drive the sample toward the channel bottom. For smaller 
particles, diffusion serves as a stronger counteracting motion than it does for larger 
particles - as a consequence, larger particles accumulate closer to the channel 
bottom and elute later. Samples are therefore separated according to their 
hydrodynamic size with smaller nanoparticles eluting before larger ones. 
All samples were measured in triplicate. Particle diameters were calculated 





2.2.8 STATISTICAL ANALYSIS 
Where appropriate, data are expressed as mean ± standard deviation (SD). 
The data was analysed using SigmaPlot Version 11 (Systat Software Inc., San 
Jose, CA, USA). Comparisons between groups were performed using Student´s t 
test (two-sided) or ANOVA with post-hoc Bonferroni adjustment for experiments 
with more than two subgroups. Results were considered statistically significant at p 
values <0.05. 
 
2.3 RESULTS AND DISCUSSIONS 
Spherical nanoparticles prepared by a double emulsion method were 
embedded in a PVA film and stretched as described above in order to prepare 
aspherical nanoparticles. PLGA was selected as a particle material for its relatively 
low glass transition temperature (Tg) of approximately 45 °C [198], important for 
the film stretching method due to the more deformability of the polymeric material 
above that temperature. In the present work, the preparation of aspherical 
nanoparticles was optimised and the produced system was characterised. 
Aspherical nanoparticles were imaged using SEM and the obtained pictures were 
analysed using ImageJ software, in order to compare imaging analysis and data 
obtained from characterisation with light-based technique, like DLS and AF4. The 
chief objective of this work was to explore the characterisation of PLGA aspherical 
nanoparticles, looking in-depth at the effect of preparation parameters on size 
distribution and evaluating the most common analytical techniques used for the 
characterisation of spherical nanoparticles. Although similar work has been 
conducted by Mathaes et al., only the characterisation of stretched commercially 
available polystyrene microparticles was conducted and discussed, with a marginal 
interest on the stretched 40 nm nanoparticles. 
After preparing spherical PLGA nanoparticles, aspherical systems were 
prepared using the film stretching method. As described in literature, a mechanical 
stimulus was applied to force a change of the nanoparticle shape from spherical to 
aspherical, taking advantage of plastic state of the PLGA and its deformability 
when heated above the Tg. Spherical PLGA nanoparticles were therefore 
immobilised in a PVA film and the cut sections were immersed into a mineral oil 
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bath warmed to 54 °C, after fixation on the previously described stretching device. 
This temperature was selected to be higher than the Tg of PLGA [198] but lower 
than the Tg of PVA (around 85 °C). The PVA was removed by centrifugation and 
the collected nanoparticles were first imaged using SEM (Figure 2.4). Spherical 
nanoparticle precursors were also imaged, for comparison.  
  
Figure 2.4 Comparative morphology of spherical and aspherical nanoparticles. 
SEM image of spherical nanoparticles (a), and aspherical nanoparticles produced from 
spherical precursors using the film stretching method (b). 
 
As shown in figure 2.4, the spherical and aspherical shape of the two 
formulations was confirmed. The asphericity of the nanoparticles in figure 
2.4b is clearly seen from the SEM picture. Only small residual of PVA was 
found in the aspherical nanoparticle solution. 
Using DLS, the hydrodynamic diameter of both spherical and 
aspherical nanoparticle dispersions was analysed based on the light intensity 
fluctuations of scattered light (Figure 2.5). Although a significant difference 
between the mean diameters of precursor spherical nanoparticles and 
aspherical nanoparticles was found using DLS, the 240 nm hydrodynamic 
  
55 
diameter measured from the aspherical system with DLS does not 
correspond with the major length observed with SEM pictures. Instead, a 
measure of 300 nm was rather found. This discrepancy in results is likely due 
to the DLS technique limitations, which assumes that the detected particles 
have a spherical shape [100]. Also the observed increase in the measured 
PDI and in its variability for aspherical nanoparticles compared with the same 
parameter measured for the spherical formulation is likely related with the 
technique limitations. These limitations make DLS not suitable for measuring 
the size of aspherical nanoparticles. Mathaes et al. [124] used the 
hydrodynamic radius, obtained with DLS, to characterise the size parameter 
of 40 nm stretched polystyrene nanoparticles. Although the current work does 
not exclude that a diameter obtained with DLS could be used to distinguish 
between spherical and aspherical nanoparticles, more accurate shape 
descriptors or techniques are needed for the characterisation of aspherical 
nanoparticles. 
 
Figure 2.5 Size and PDI of aspherical and spherical PLGA nanoparticles. 
Size, represented by grey bars, and PDI, represent by black data points, of aspherical and spherical 
nanoparticles. (n=3). *=p<0.05 
Following these initial investigations, in which SEM image analysis was 
determined to give more accurate and in-depth sizing information with respect to 





























aspherical systems was optimised (with respect to the parameters of stretching 
rate, oil bath temperature and concentration of film-embedded nanoparticles). In 
particular the influence of the film thickness on the size distribution of resulting 
aspherical nanoparticles was investigated via SEM image analysis. 
The film thickness, according to Champion et al. [123], is a key parameter 
influencing the shape and size of produced aspherical particles. To have a more 
in-depth look on this, after producing the film, the thickness of the cut sections was 
measured using MiniTest 3100. The thickness of film sections was found to fall into 
two broad categories; sections were therefore divided into two groups (between 50 
µm and 90 µm and between 90 µm and 120 µm) prior to stretching. After 
separately stretching film sections from each group, and recovering and purifying 
the stretched nanoparticles, the shape descriptors as outlined in Figure 2.3 were 
calculated (Table 2.1). As mentioned, two types of shape descriptors given by the 
ImageJ software were selected to describe the aspherical nature of the 
nanoparticles. Feret´s diameter and minor Feret’s diameter were measured as the 
longest and the shortest distance between two parallel tangents of the particle at 
an arbitrary angle, respectively; in addition, due the similarity between the 
observed shape of aspherical nanoparticles and an ellipsoid, the major and minor 
axis and AR were also considered as appropriate shape descriptors. The objective 
of employing these various measures was to compare shape descriptors (Feret´s 
diameters), where the nanoparticles are directly measured, with shape descriptors 
(major and minor axis), where the nanoparticles are fitted to a known shape, and 
therefore an interpolation error can be made. This latter method has the 
advantages of giving additional information such as the AR and the volume of the 
nanoparticles (see chapter 3). In cases where the shape of aspherical 
nanoparticles perfectly fits with the dimensions of an ellipsoid, the Feret´s 
diameters and the major and minor axis measures show a high degree of 
similarity; in contrast, a less accurate fit to an ellipsoidal shape will result in high 
degree of difference between Feret’s diameters and major and minor axis 
measures. In this work, the longest axis of the nanoparticles (as measured by both 
major axis and Feret´s diameter) and the shortest axis (measured by both minor 
axis and minor Feret´s diameter) were measured as being approximately 300 nm 
and 130 nm respectively, indicating that the two shape descriptors are equivalent. 
Surprisingly, no significant differences in shape parameter were found for 
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aspherical particles produced by stretching of film sections of 50-90 µm thickness 
as compared to 90-120 µm thick sections. This indicates a lack of influence of the 
film thickness on the stretching procedure, and demonstrates that the 
nanoparticles have an ellipsoidal shape. Using the major and minor axis values 
also the asphericity of the nanoparticles was calculated, with an AR of around 2.5 
found for both groups (Table 2.1). 
As no difference was found between the major axis and the Feret´s 
diameter or between the minor axis and the minor Feret´s diameter and due to the 
ellipsoidal shape evidenced by SEM images, for future characterisation of the 
aspherical nanoparticles the major and minor axis were chosen as representative 
shape descriptors.  
 
Table 2.1 Shape descriptors of aspherical nanoparticles. 
Shape descriptors were measured with ImageJ software, as a function of the thickness of the film in 
which nanoparticles were embedded for stretching. Data represents mean ± SD (n=2 batches, each 
consisting of approximately 200 nanoparticles).  
Film thickness 50-90 µm 90-120 µm 
Minor Feret´s diameter 
(nm) 
145.38 ± 12.09 126.29 ± 9.27 
Feret´s diameter (nm) 320.29 ± 21.54 299.65 ± 24.65 
AR 2.43 ± 0.03 2.62 ± 0.4 
Minor axis (nm) 128.44 ± 5.90 113.35 ± 8.6 
Major axis (nm) 312.24 ± 17.68 294.19 ± 26.84 
 
With this in mind, the distribution of aspherical nanoparticle major and minor 
axis measurements was further investigated (Figure 2.6). To define the distribution 
width, D10, D50 and D90 values were extrapolated from the cumulative intensity. 
The D50 is defined as the diameter value below which half of the particle 
population lies. Similarly, 90% of the particle population lies below the D90, and 
10% of the population lies below the D10. 
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Distributions of aspherical nanoparticles show that only 10% of the 
population has a major axis below 180 nm and a minor axis below 80 nm. Instead 
the 90% of the produced nanoparticles has a major axis below 480 nm and a 
minor axis below 157 nm. The D50 extrapolated from both major and minor axis 
distributions was found around 310 nm for the major axis and 118 nm for the minor 
axis. 
 
Figure 2.6 Distribution of shape descriptors. 
Major (a) and minor (b) axis distributions of the aspherical nanoparticles are shown, as well as D10, 
D50 and D90 values for each descriptor. Analysis was done from data acquired from SEM images 
using ImageJ software (two batches, n=5 images, each image containing 40 nanoparticles). 
An alternative method to characterise aspherical nanoparticles, as 
described by Mathaes et al. [124] and also by other authors [199, 200], is via an 
AF4 system coupled with MALLS and QELS detectors. This technique allows a 
high-resolution separation depending on the size of the nanoparticles, within a very 
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thin flow stream against which a perpendicular force field is applied [201]. After the 
flow separation, the size of the nanoparticles is detected by two different detectors, 
MALLS and QELS, and a chromatogram illustrating the size parameters of 
nanoparticles as a function of their elution time is obtained. Moreover using the 
AF4 software approximation, the shape of the nanoparticles can be approximated 
to a rod and the rod length with its distribution can be extrapolated. This technique 
was therefore also employed in the current work for analysis of aspherical 
nanoparticles. Spherical nanoparticles were additionally analysed, for comparison 
purposes. 
Although Mathaes et al. [124] were able to show a difference in the peak of 
the chromatograms and elution time of commercially available, 40 nm spherical 
and 3 times stretched aspherical nanoparticles, this was not found to be the case 
in the present work for spherical and aspherical PLGA nanoparticles. These 
contrasting findings are thought to be a result of the difference in nanoparticles 
material (polystyrene vs PLGA), fabrication and elongation (two or three times 
elongated) during the stretching procedure, and the important impact on the 
detection of the AF4 (Figure 2.7a). In the current work, the Astra software was 
used for data analysis and a rod model was selected in order to determine the 
length and size distribution of aspherical nanoparticles (Figure 2.7b). No difference 
in the curve for size distribution was found for three different batches of analysed 
aspherical particles, demonstrating the reproducibility of the film stretching method. 
Moreover the rod length was compared with the major axis measure extrapolated 
from SEM images, as discussed above (Figure 2.7c). No significant difference was 
found between the two parameters. Although it was not possible to differentiate 
from the chromatogram the shape of the nanoparticles, AF4 could be used to 




Figure 2.7 AF4 chromatograms of spherical and aspherical nanoparticles, and comparison of shape 
descriptors measured with AF4 and SEM image analysis. 
Chromatograms (a) of aspherical and spherical nanoparticles (NPs), with (b) the rod length 
distribution of three independent batches of aspherical nanoparticles extrapolated using the ASTRA 
software shown; (c) comparison between the major axis measurement of aspherical nanoparticles as 
extrapolated from SEM images, and the rod length parameter of aspherical nanoparticles as 




To summarise, three different techniques (DLS, SEM and AF4) were used 
to characterise the produced aspherical nanoparticles, in order to identify a method 
which would provide a quick and easy means to differentiate between spherical 
and aspherical nanocarriers, while also providing an accurate and robust measure 
of aspherical particle shape parameters. 
In considering the advantages and disadvantages of each technique, the 
expensive instrumentation and time required for the SEM image analysis approach 
are compensated for by the ability to actually visualise the size and shape of the 
particle sample, which is one of the fundamental requirements for the confirmation 
and characterisation of an aspherical system. Use of a readily available and rapid 
technique like DLS would reduce the cost and the analysis time, however due to 
the aspherical nature of the system this technique cannot be considered to give a 
reliable size result. The automatic approximation to a sphere is a limitation for the 
analysis of aspherical nanoparticles. Unless this problem is overcome, DLS 
technique could potentially be used only to distinguish between spherical 
precursors and stretched aspherical nanoparticles. The true extent of the shape 
change however cannot be explored in detail with sufficient accuracy. This 
problem could be avoided in the AF4 method using the appropriate software 
approximation; however, as it is evident from the similarity in the obtained 
chromatograms of eluted spherical and aspherical nanoparticles, AF4 analysis 
would in itself need to be supported by another technique, such as SEM. 
 
2.4 CONCLUSION 
In this chapter, a method to produce aspherical nanoparticles from spherical 
precursors was employed and optimised. Various methods were then investigated 
for the characterisation of aspherical nanoparticles and an analytical method 
capable of differentiating between the shape of aspherical and spherical 
nanocarriers was identified. 
For particle preparation, the film stretching method was selected and a 
stretching apparatus was subsequently fabricated. A procedure for obtaining 
aspherical nanoparticles by stretching of spherical precursors was then optimised, 
in order to obtain aspherical particles in the nano-size range. Physical 
characterisation of the produced aspherical nanoparticles was conducted via 
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microscopic analysis (SEM and ImageJ) as well as light-based techniques (DLS 
and AF4), in order to select the best analysis method. The possibility to produce a 
suitable shape descriptor (such as major axis or rod length) and the possibility to 
distinguish between the stretched aspherical and precursor spherical nanoparticles 
were the two main criteria for choosing the analysis methods. DLS was determined 
to be inappropriate for characterisation of the produced aspherical systems due to 
its limitation on the shape recognition capability; AF4 could potentially be used for 
determination of the major axis length of the aspherical nanoparticles, but its use 
was limited by the small amount of data that can be extrapolated and the 
impossibilities of distinguish between spherical and aspherical particles; the use of 
SEM imaging in conjunction with ImageJ analysis is considered the most accurate 
and descriptive technique for visualising and measuring shape parameters of the 
aspherical nanoparticles.  
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The script code for 3D model and calculation of the surface occupancy were 
conducted by Dr Martin Empting from the Drug Design and Optimisation 
department of HIPS. 
 
Parts of this chapter have been published in Pharmaceutical Research, with 
the title "Aspherical and Spherical InvA497-functionalized Nanocarriers for 




While delivery of anti-infective drugs via the oral route is an attractive and 
logical option for the treatment of gastrointestinal infections, the intracellular 
localisation of some pathogens, including particular species of bacteria, may act to 
limit the efficacy of orally-administered therapeutic agents. In the case of 
intracellular infections where the bacteria are hidden inside the host epithelial cells, 
encapsulation of drug candidates into nanoparticles functionalised with specific 
biomolecules (a strategy also referred to as active or ligand targeting) is a potential 
way to increase the treatment efficacy. In particular, by using biomolecules which 
have bioadhesive or invasive properties, the cellular uptake of nanoparticles 
together with their anti-infective cargo can be enhanced [91, 202]. 
In recent years bacterial molecules and even bacterial invasion systems 
have been explored as new strategies for active targeting. It has been 
demonstrated for example that Salmonella-like nanoparticles, obtained by coupling 
Salmonella enteritidis flagellin (the main component of the flagellar filament and 
normally used by this bacteria to colonise epithelial host cells) on nanoparticles, 
could overcome the gastrointestinal mucosal barrier and penetrate into the 
intestinal tissue in rats [203].  
Proteins normally expressed on the surface of bacteria, and used by the 
bacteria themselves to overcome the mammalian mucosal barriers or to invade 
mammalian cells, have also been coupled on the surface of nanoparticles, to 
produce what are commonly known as bacteriomimetic systems [204]. Invasin for 
example, an invasion protein normally expressed on the surface of Yersinia spp., 
was one of the first bacterial proteins used in order to produce these 
bacteriomimetic systems, via coupling onto latex beads [90]. The uptake and the 
influence of the invasin concentration on the surface of beads were studied, 
showing the advantages of having such a protein on surface of the beads on the 
cellular uptake of the system. While these proteins can be used in their entirety, 
fragments of bacterial proteins may also be employed to enhance nanoparticulate 
system uptake. In this respect, it has been demonstrated that a C-terminal 
fragment of invasin, also known as InvA497 [60], can improve cellular uptake when 
covalently coupled onto liposomes or PLGA nanoparticles [90, 92, 205]. As 
demonstrated by Labouta et al., liposomes with InvA497 covalently coupled onto 
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the surface showed promising results, improving the uptake of the liposomes in 
comparison with the formulation without InvA497 [90]. 
The bacteriomimetic systems produced so far, such as InvA497-
functionalised liposomes or Salmonella-like nanoparticles, are able to mimic only 
the way in which bacteria penetrate inside mammalian cells (or in some cases, 
such as through the use of lipid-based particle systems, the composition of 
bacteria), however no studies on other nanoparticle parameters, such as shape, 
have been conducted. Although rod-like bacteria are quite common in nature, in 
particular in enteropathogenic bacteria such as Yersinia and Shigella spp. as well 
as Escherichia coli, to the best of the author’s knowledge no studies have yet been 
conducted using aspherical particle systems with bacterial moieties on the surface, 
and it remains unknown whether any correlation between carrier system shape 
and the uptake mechanism typical of some bacteria exists. 
In order to study and explore unsolved questions regarding the importance 
of shape on surface functionalised nanoparticle on uptake into epithelial cells, 
polymeric systems with an aspherical shape, functionalised with biomolecules 
have been recently produced and studied. Polymeric nanoparticles surface-
functionalised with specific ligands, such as biotin or a trastuzumab antibody, have 
been recently prepared and studied for particular application [159]. These 
molecules were used as model proteins due to their well-known and well-
characterised mechanism of action. Such studies have not however been 
extended to the employment of bacteria-derived molecules, like InvA497, in order 
to access intracellular pathogens. 
The idea of using a bacteriomimetic system, which has an aspherical shape 
typical of some bacteria and penetrates inside the mammalian cells using the way 
of bacteria, could create an interesting outlook for developing innovative drug 
delivery systems which is able to kill intracellular bacteria.  
Therefore, the following work was focused on the method for coupling 
InvA497 on the surface of aspherical and spherical nanoparticle and 
characterisation of such bacteriomimetic systems. Aspherical and spherical (as 
comparator) PLGA nanoparticles were functionalised with InvA497 using an 
optimised coupling procedure and afterwards characterised for their morphology. 
The surface functionalisation was optimised and the covalent coupling of InvA497 
on the surface of both aspherical and spherical was probed using IR spectroscopy. 
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After measuring the size of aspherical and spherical systems, a 3D model was 
generated in order to study the InvA497 distribution on the surface of aspherical 
and spherical nanoparticles.  
 
3.2 MATERIALS AND METHODS 
3.2.1 MATERIALS 
For the preparation of nanoparticles, PLGA Resomer RG 503 H 
(lactic/glycolic acid, 50/50 wt/wt; MW 40 300 Da; inherent viscosity 0.41 dl/g; from 
Evonik Industries AG, Darmstadt, Germany), fluoresceinamine isomer I and N´-(3-
Dimethylaminopropyl)N-ethylcarbodiimide HCl (FA and EDC respectively, both 
from Sigma-Aldrich, Steinheim, Germany) were used. 
PVA (Mowiol® 4–88, Kuraray Specialties Europe GmbH, Frankfurt, 
Germany), glycerol and mineral oil (both from Sigma-Aldrich, Steinheim, Germany) 
were used for the stretching procedure. 
For the coupling procedure bovine serum albumin (BSA) and 4-(4,6-
Dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride (DMTMM) from 
Sigma-Aldrich (Steinheim, Germany) were used. To quantify the amount of 
InvA497 protein a bicinchoninic acid (BCA) kit was utilised (QuantiPro™; Sigma-
Aldrich, Steinheim, Germany). 
All the other solvents and chemicals used were of at least analytical grade, 





3.2.2 PREPARATION OF FLUORESCENTLY LABELLED 
NANOPARTICLES 
To enable fluorescent labelling of nanoparticles, fluoresceinamine-PLGA 
(FA-PLGA) was prepared according to Weiss et al. and Horisawa et al. [206, 207]. 
Briefly 3.07 g of PLGA, 0.0583 g of FA and 0.0408 g of EDC were dissolved in 30 
ml of acetonitrile and incubated at room temperature (RT) for 24 h. The resulting 
FA-PLGA was precipitated by addition of water and separated by centrifugation 
(20 min, 16 000 g, RT; Rotina 420R, Hettich Zentrifugen, Tuttlingen, Germany). 
The excess of FA and EDC was then removed by repeated dissolution of the 
mixture in acetone and precipitation in ethanol, followed by centrifugation (10 min, 
16000 g, RT) in order to sediment the formed FA-PLGA. The final product was 
then lyophilised overnight and stored in the freezer at -20 °C. 
Fluorescently labelled nanoparticles (spherical = S, aspherical = A) were 
then prepared as described in Chapter 2, using a mixture of FA-PLGA and PLGA 
(0.25: 0.75 weight ratio). 
 
3.2.3 NANOPARTICLE SURFACE FUNCTIONALISATION 
PLGA nanoparticles were surface functionalised with InvA497, a 497 amino 
acid fragment of the C-terminus of invasin, an invasion protein of Y. 
pseudotuberculosis, which was extracted and purified from E. coli BL21 as 
described previously [90, 208]. BSA was however first used for optimisation of the 
coupling procedure, before employing InvA497 itself.  
A similar stretching procedure to that described in Chapter 2 was employed 
for preparing aspherical BSA-functionalised nanoparticles (AB) or InvA497-
functionalised nanoparticles (AI), with some modifications. Three different 
preparation and coupling procedures were tested: 
 As illustrated in Figure 3.1a, 1 ml of aspherical nanoparticles (A), 
prepared as described in Chapter 2, was first diluted with 0.9 ml of water 
and then incubated for 2 h with 0.6 ml of a 5 mg/ml solution of the 
carboxyl group-activating agent DMTMM, at RT. Afterwards a solution of 1 
mg/ml BSA was added in order to have a final concentration of 320 µg/ml, 
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and the dispersion was stirred overnight in an ice bath. The excess of 
DMTMM reagent and unbound BSA was then removed by centrifugation 
(using Centrisart® tubes 300 kDa MWCO, 1 605 g and 4 °C for 10 min, 
three cycles). 
 As shown in Figure 3.1b, 1 ml of spherical nanoparticle dispersion was 
first diluted with 0.9 ml of water. The diluted dispersion was then 
incubated for 2 h with 0.6 ml of a 5 mg/ml solution of DMTMM, at RT. BSA 
was then added to a final concentration of 320 µg/ml, stirred overnight in 
an ice bath, and then subjected to centrifugation as described in method 1 
in order to remove unbound BSA. The surface functionalised spherical 
nanoparticles were then immobilised into the PVA-glycerol film as 
described in Chapter 2; subsequent stretching of the nanoparticles, 
dissolution of films and removal of excess PVA were all conducted as also 
described in Chapter 2. 
 As seen in Figure 3.1 c, 1 ml of spherical nanoparticle dispersion was 
incubated with DMTMM, as described above, and then immobilised in a 
PVA-glycerol film, as described in Chapter 2. Stretching of the 
immobilised nanoparticles, dissolution of films and removal of excess PVA 
were then all conducted as also described in Chapter 2. The produced 
aspherical nanoparticles were stirred overnight in ice bath with BSA or 
InvA497 (320 µg/ml). Unbound BSA or InvA497 was then removed by 
centrifugation as described in methods 1 and 2 (using Centrisart® tubes 





Figure 3.1 Schematic of aspherical nanoparticle surface functionalisation with InvA497. 
a) In method 1, BSA was coupled on the surface of aspherical nanoparticles by first activating 
surface-exposed carboxyl groups with DMTMM, followed by the addition of BSA; b) in method 2, BSA 
was coupled on the surface of spherical nanoparticles by first activating surface-exposed carboxyl 
groups with DMTMM, followed by the addition of BSA and particle stretching; c) in method 3, surface 
coupling of BSA or InvA497 onto aspherical nanoparticles was performed by activating carboxyl 
groups of spherical nanoparticles and particle stretching, followed by incubation with BSA or 
InvA497. 
 
In order to surface functionalise spherical nanoparticles (S), 1 ml of 
nanoparticle dispersion was first diluted with 0.9 ml of water. The diluted dispersion 
was then incubated for 2 h with 0.6 ml of a 5 mg/ml solution of DMTMM, at RT. 
Nanoparticle dispersions were then diluted with water (1:8, 1:4, 1:2, 2:3 or 1:1 
water:nanoparticles; v:v), to a final volume of 2.5 ml. After dilution, BSA or InvA497 
were added in order to have a final concentration of 320 µg/ml, and the dispersion 
was stirred overnight in an ice bath. The excess of DMTMM reagent and unbound 
BSA or InvA497 was removed by carrying out three centrifugation cycles as 
described above. The resulting spherical, BSA- InvA497-functionalised 




3.2.4 PROTEIN QUANTIFICATION 
The amount of BSA or InvA497 coupled to the surface of SI and AI 
formulations was quantified using a BCA kit, in accordance with the manufacturer's 
instructions (QuantiPro™; Sigma-Aldrich, Steinheim, Germany) and as previously 
described [90, 209]. After preparing a calibration curve in accordance with the 
manufacturer´s instruction, the concentration of BSA or InvA497 was calculated 
and after dividing the concentration for ml of nanoparticle solution the amount of 
coupled BSA or InvA497. From the amount of InvA497 coupled protein, the 
molecules of surface-bound InvA497 was calculated dividing for the amount for the 
molecular weight of InvA497 and multiplying for the Avogadro number. 
 
3.2.5 IMAGING OF NANOPARTICLES 
The morphology of both SI and AI formulations was visualised using SEM 
(Zeiss EVO HD 15, Carl Zeiss AG, Oberkochen, Germany) at an accelerating 
voltage of 5 kV. Samples were diluted and dried overnight prior to imaging, and 
were sputter coated (Quorum Q150R ES, Quorum Technologies Ltd, Laughton, 
United Kingdom) with gold. 
For the AI formulation, major and minor axis lengths as well as the AR were 
determined from SEM images using ImageJ software (Fiji). 
 
3.2.6 NANOSIGHT ANALYSIS 
The number of nanoparticles for SI and AI was counted using nanoparticle 
tracking analysis (NTA, NanoSight LM 10, Malvern Instruments Ltd, 
Worcestershire, United Kingdom). The concentration of nanoparticles within 
appropriately diluted samples was first calculated by the NTA software. This was 
then converted into a number of nanoparticles in the total dispersion, dividing the 
concentration for the ml of solution. The previously found quantified molecules of 
surface-bound InvA497, previously found with BCA assay, was divided for the 
number of nanoparticles in the total dispersion in order to estimate the number of 
InvA497 molecules per nanoparticle for both SI and AI formulations.  
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3.2.7 FT-IR SPECTROSCOPY 
To confirm the formation of a covalent, amide bond between amine groups 
of InvA497 and the carboxyl group of PLGA molecules exposed on nanoparticle 
surfaces, sample of AI, SI and S formulations as well as InvA497 alone were 
freeze dried and afterwards the infrared spectra were collected, using a Fourier 
Transform Infrared (FT-IR) spectrometer (Perkin Elmer system 2000). Each 
spectrum was collected in a range between 4000 and 600 cm−1 with a resolution of 
1 cm−1 (100 scans per sample). 
 
3.2.8 DLS 
The size distribution of SI nanoparticle dispersions was determined by DLS 
using a Zetasizer Nano (Malvern Instruments Ltd, Worcestershire, United 
Kingdom), as described in Chapter 2. 
 
3.2.9 CALCULATION OF SURFACE OCCUPANCY 
Using the estimated number of molecules per nanoparticle and the gyration 
radius of InvA497 [210], the total area occupied by InvA497 molecules was 
calculated. This was divided by the surface area of SI and AI nanoparticles, 
calculated using sphere and ellipsoid shape descriptors respectively, in order to 
obtain the total percentage of nanoparticle surface area occupied by InvA497 in 
each case (see appendix). 
 
3.2.10 GENERATION OF 3D MODEL OF INVA497-
FUCTIONALISED NANOPARTICLES 
A 3D model of InvA497-functionalised SI and AI nanoparticles was 
generated via a self-written script for PovRay 3.7 (see appendix). In order to 
produce the model, X-ray coordinates of InvA497 (PDB ID: 1CWV) [65] were 
exported and scaled to the PovRay format using YASARA structure (YASARA 
Biosciences) [210]. After modelling of spherical and aspherical nanoparticle 
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shapes, the number of InvA497 molecules calculated to be present on each 
nanoparticle (as described above – 235 and 198 molecules for SI and AI 
respectively) were randomly distributed on the spherical and aspherical objects. 
The picture was rendered with subsurface light scattering turned on. 
 
3.2.11 STATISTICAL ANALYSIS 
Where relevant, data are expressed as mean ± standard error of the mean 
(SE). Also where appropriate, data was analysed using SigmaPlot Version 11 
(Systat Software Inc., San Jose, CA, USA) for statistical significance. Comparisons 
between groups were performed using Student´s t test (two-sided), or one-way 
ANOVA with post-hoc Bonferroni adjustment for experiments with more than two 
subgroups. Results were considered statistically significant at p values <0.05. 
 
3.3 RESULTS AND DISCUSSIONS 
The surface of A and S nanoparticles was decorated with a fragment of the 
bacterial invasion protein invasin, known as InvA497, to produce formulation 
referred to as AI and SI respectively. In order to allow for visualisation of 
nanoparticles in later work (while still allowing for nanoparticle surface 
functionalisation), nanoparticles were prepared using PLGA mixed with a small 
amount of FA-PLGA. 
InvA497 presents a receptor binding domain and three important amino 
acids involved in the receptor-mediated uptake (Phenylalanine 808, Aspartate 811 
and Aspartate 911) [60] on the C-terminal part which must remain free in order to 
preserve the invasive properties. Moreover C-terminal part must also be direct 
through the outer part of the particle. Therefore, free PLGA carboxyl groups on the 
surface of AI and SI nanoparticles were used in the present study to couple to 
amine groups of InvA497 molecules. Due to the non-reactive nature of the PLGA 
carboxyl groups and the amine groups of InvA497, a coupling agent, DMTMM, was 
used. As with most commonly employed coupling methods, the reaction principle 
first involves the activation of the carboxyl group, followed by the interaction 
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between this activated group and an entity containing an amine group to form an 
amide bond. 
In the case of the AI, the coupling method was first optimised in order to 
maintain the aspherical shape of the nanoparticles. In an initial approach (Method 
1, Figure 3.1a), freshly prepared A nanoparticles were incubated with DMTMM and 
then with BSA protein (AB), a model protein with the same molecular weight of 
InvA497 and used in previous work for coupling optimisation and demonstrated in 
previous work to be an appropriate protein model for coupling optimisation. This 
strategy was employed due to the difficulties on produce and purifies InvaA497 
compared with the commercial available BSA. Although more than 300 µg, 
corresponding to a 50% functionalisation efficiency (data not showed) of BSA was 
found to be coupled to the surface of AB, SEM images showed reversion to a 
spherical shape due to the coupling procedure (Figure 3.2). 
 
 
Figure 3.2 Morphology of AB nanoparticles produced using coupling method 1. 
SEM image of aspherical BSA-functionalised nanoparticles (AB) after direct functionalisation of 
aspherical nanoparticles (A) (as described in Figure 3.1a). 
 
As direct functionalisation of aspherical nanoparticles seemed to have a 
negative effect on the shape, two further coupling methods were trialled in order to 
produce AB. In both methods, carboxyl groups of spherical PLGA nanoparticles 
were activated with DMTMM, following which two different approach were 
employed: for method 2 BSA was first coupled and afterwards the particles were 
immobilised into PVA film and stretched (Figure 3.1b); for method 3 particles were 
first immobilised into PVA film and stretched, followed by BSA surface coupling 
(Figure 3.1c). During coupling reaction between the amine group of DMTMM and 
the carboxylic group of PLGA on the surface of the aspherical nanoparticles, a 
change of the interfacial tension of the nanoparticle occurs, which could induce a 
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recovery of the spherical shape. In both method 2 and 3, the first step of the 
functionalisation is performed before the stretching of the nanoparticles when the 
system still has a spherical shape. 
As shown in Figure 3.3, the highest amount of coupled BSA was reached 
with method 3 (approximately 480 µg of BSA coupled), in which the two steps of 
the functionalisation process (activation of PLGA carboxylic acid groups and final 



































Figure 3.3 Characterisation of BSA functionalised aspherical nanoparticles prepared via different 
coupling methods. 
The amount of total coupled BSA on the surface of AB nanoparticles using two different preparations 
and coupling procedures. In both methods spherical nanoparticles were first incubated with DMTMM. 
In method 2 the nanoparticles were then incubated with BSA and afterwards stretched; in method 3, 
spherical nanoparticles were stretched and then incubated with BSA. Results represent the mean ± SE 
(n=3). 
 
An even higher amount of coupled protein was found when InvA497 was 
substituted for BSA using method 3, and the aspherical morphology of resulting AI 




Figure 3.4 Morphology and coupling characterisation of AI. 
a) SEM image of aspherical InvA497 functionalised nanoparticles (AI). b) The amount of total 
coupled InvA497 on the surface of AI nanoparticles was measured via the BCA assay. Results 
represent the mean ± SE (n=3). 
 
As method 3 resulted in the production of aspherical nanoparticles with the 
highest amount of surface coupled BSA, and an even higher amount of coupled 
InvA497, this method was selected as an optimum preparation procedure for AI. 
Moreover comparing method 3 with method 2, as the stretching procedure is 
performed before the final step of the functionalisation, the protein coupled on the 
surface of the particle is not exposed to the harsh condition of the stretching 
method. The high temperature and the thermomechanical stress used during the 
production of aspherical nanoparticles could have led to a degradation and loss of 
activity of the BSA or InvA497 protein. 
In order to produce a truly comparable spherical formulation with a similar 
amount of surface coupled protein to the optimised aspherical nanoparticles, the 
functionalisation procedure for production of SI was also optimised by first using 
BSA (SB). After incubating S with DMTMM, the nanoparticle dispersion was diluted 
to varying extents and then incubated with the same amount of BSA as used for 




Figure 3.5 Coupling characterisation of SB. 
Nanoparticle dispersions were diluted with water by dilution factors of 1:8, 1:4, 1:2, 2:3 and 1:1 
(water:nanoparticles, v:v), following the carboxylic group activation. The amount of coupled BSA on 
the surface of spherical BSA functionalised nanoparticles (SB) was then measured with the BCA 
assay. Results represent the mean ± SE (n=3).  
 
It was found that dilution of SB nanoparticle dispersions by factors of 2:3 
and 1:1 prior to coupling had comparable amounts of surface coupled BSA to AB 
nanoparticles. A dilution factor of 2:3 was chosen for further use due to the similar 
amount of nanoparticles in the dispersion as AB formulation, as calculated by NTA 
(approximately 2x106 nanoparticles). 
After replacing BSA with InvA497 on the surface of spherical nanoparticles, 
the amount of InvA497 on the surface of AI and SI was compared (Figure 3.6). For 
both AI and SI, approximately 500 µg of InvA497 in total was found to be bound to 
the surface of nanoparticles. The number of molecules of InvA497 per nanoparticle 
and the coupling density were then estimated, using the number of coupled 
molecules of InvA497, extrapolated from the measured amount of InvA497, and 
the number of nanoparticles in solution, extrapolated with the NTA and its 
software. Combining the total amount of surface-bound InvA497 together with 
NTA-measured nanoparticle numbers, it was further estimated that approximately 
200 molecules of InvA497 were present on the surface of each SI or AI 
nanoparticle. Comparing the functionalisation of SI and AI with previously prepared 
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invasin-functionalised latex particles [211], where the authors show the optimal 
number of invasin complete protein per nanoparticles to reach the highest uptake, 
PLGA AI and SI formulation present a lower amount compared with first systems. 
Considering the already proven effective intracellular delivery of the 
aforementioned liposomal formulation with a relatively low number of InvA497 
molecules, the approximate number of InvA497 molecules estimated to be on the 
surface of SI and AI was not considered to preclude InvA497-receptor mediated 



































































Figure 3.6 Characterisation of InvA497 functionalisation on nanoparticle. 
The amount of total coupled InvA497 (grey bars) on the surface of AI and SI nanoparticles was 
measured via the BCA assay, and afterwards molecules of InvA497 per nanoparticle (black points) 
were estimated using the number of nanoparticles (as determined using NTA). Results represent the 
mean ± SE (n=3). 
 
To confirm the formation of an amide bond between the carboxyl group of 
PLGA and the amine group of InvA497, and therefore a successful coupling of 
InvA497 on the surface of AI and SI, IR spectra were collected for both 
functionalised nanoparticles and spherical non-functionalised nanoparticles alone 





Figure 3.7: IR spectra of nanoparticles and InvA497. 
IR spectra of non-functionalised spherical nanoparticles (S, pink line), InvA497 protein alone (green 
line) and functionalised aspherical (AI) and spherical (SI) nanoparticles (blue and pink lines 
respectively) were collected. 
 
As shown in the IR spectra, the characteristic amide C=O peak (around 
1600 cm-1) and the amine band (between 3000 and 3500 cm-1) were found only in 
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AI and SI, but not on the formulation without functionalisation. These spectra 
demonstrate therefore that InvA497 was successfully coupled on the surface of 
both AI and SI; however, additional adsorption of the protein fragment on the 
surface of AI and SI cannot be ruled out. 
 
After demonstrating the continued presence of aspherical or spherical 
shape of nanoparticles following successful surface functionalisation, physical 
characterisation of both AI and SI was conducted. Size was measured using SEM 
image analysis for AI and DLS for SI, with values of 300 nm and 110 nm found for 
the major and minor axis length of AI, and a diameter of 180 nm measured for SI 
(Figure 3.8). These values were found to be comparable to respective A and S 
formulations, indicating no influence of surface functionalisation on the dimensions 
of either spherical or aspherical systems. The asphericity of the AI nanoparticles 
was further determined from measured major and minor axis lengths, by 
calculation of the nanoparticle AR – this was found to be approximately 2.6, a 






Figure 3.8 Size of AI and SI nanoparticles. 
The major and minor axis dimensions of AI were assessed and compared with the diameter of 
precursor SI (horizontal line). Major and minor axis measurements represent mean ± SE (n =98). 
 
Illustrative 3D models of the surface-modified carrier systems were then 
generated (Figure 3.9), using the experimentally-determined dimensions of AI and 
SI and the amount of InvA497 on the surface, as determined by BCA assay, 





Figure 3.9 3D model of AI and SI. 
Particle surfaces are coloured grey and the randomly distributed InvA497 molecules are shown in 
yellow, with the C-terminal integrin-binding regions highlighted in red. 
 
As part of the model generation particle surface areas were assumed to be 
equivalent to a sphere for SI or to an ellipsoid for AI; it was also simulated that 
each InvA497 molecule occupies a circular area as dictated by its gyration radius. 
Using these approximations, the degree of particle surface coverage by InvA497 
protein was estimated to be approximately 39% for both AI and SI nanoparticles 
(for calculation see Appendix). The protein fragments were randomly orientated on 
particle surfaces, with some InvA97 C-terminal regions (in red) directed externally, 
demonstrating coupling with the correct orientation on particle surfaces; others 
however have the integrin binding region aligned with the nanoparticle surface, 






In this chapter, spherical and aspherical nanoparticles surface-
functionalised with InvA497 were prepared and characterised. In particular, a 
stretching procedure and coupling reaction were combined in order to obtain a 
system which can mimic the aspherical shape of bacteria as well as their natural 
invasion mechanism.  
Characterisation of both morphology and coupled amount of InvA497 was 
conducted for both AI and SI formulations. On both AI and SI, InvA497 was 
coupled on nanoparticle surfaces using a coupling reaction between the carboxylic 
acid group of PLGA and the amine group of InvA497. The coupling procedure was 
optimised, first with BSA and then with InvA497, so that a similar total amount of 
invasin fragment was found to be present on the surface of both nanoparticle 
types. Approximately 200 molecules of protein were estimated to be present on the 
surface of each individual SI and AI nanoparticle. Afterwards the coupling of 
InvA497 with PLGA molecules was confirmed by measuring IR spectra, although 
the existence of a fraction of surface adsorbed InvA497 could not be excluded. 
Using SEM image analysis and DLS, the produced functionalised 
nanoparticles were found to have dimensions of approximately 300 and 110 nm for 
the major and minor axes of AI respectively, and around 180 nm for the diameter 
of SI. Combining the produced dimension data and the quantified amount of 
coupled InvA497, a 3D model of the aspherical and spherical nanoparticles was 
generated. Such a model shows the distribution of InvA497 on the surface of AI 
and SI, as well as the likely orientation of the C-terminal region of InvA497. 
So far, the current work has been focused on the development of 
bacteriomimetic nanoparticles, exhibiting an aspherical shape and InvA497 protein 
on the surface. The spherical corresponding formulation has also been prepared 
as a comparator and the two systems have been optimised in order to possess a 
similar amount of surface coupled InvA497. Further chapters in this thesis will 
focus on testing the uptake of both types of bacteriomimetic nanoparticles in an 





4. UPTAKE OF INVASIN-FUNCTIONALISED 
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The ability of bacteria to penetrate into and infect host cells is an important 
step in the infection cycle in many cases. For example, specific molecules, like 
invasin, expressed on the surface of some species of enteropathogenic bacteria, 
such as Yersinia spp, enhance the bacteria cellular permeation and the 
establishment of the intracellular infection in the GI tract [213]. Each 
enteropathogenic bacterial species has a different invasion mechanism, which 
involves specific host cell-bacteria interactions. As examples, both Shigella and 
Salmonella spp. use similar small actin regulatory proteins to invade M cells of the 
intestinal epithelium; however, Shigella spp. appears to be internalised without 
destroying the host cells, in contrast to Salmonella spp., which presents a more 
invasive mechanism [214, 215]. 
 
As a further example, Yersinia spp. express various monomeric invasins 
and adhesins, as well as highly sophisticated macromolecular machinery such as 
the commonly expressed type III secretion system, all of which facilitate interaction 
between the pathogen and host cells [216]. Invasin is one of these expressed 
invasive proteins, which plays an important role in the complex internalisation 
mechanism utilised by Y. enterocolitica and Y. pseudotuberculosis [217]. Invasin is 
an outer membrane protein which is normally expressed at the early stationary 
phase of bacterial growth [218]. It consists of 986 amino acids, however only the 
last 192 amino acids of the protein C-terminus are responsible for binding with β1 
integrin receptors on the surface of M cells [60, 219]. Interaction between invasin 
and these receptors leads to a rearrangement of the cell cytoskeletal system and 
the consequent internalisation of the pathogen [217]. As β1 integrins are only 
expressed on the basolaterial side of epithelial cells, binding and internalisation of 
bacteria can only occur when the integrity of the epithelial barrier is compromised, 
like a result of inflammation. Although only the last 192 amino acids are effectively 
involved with the binding procedure, it has been shown that an invasin fragment 
containing the last 197 amino acids of the parent protein C-terminus was not able 
to promote as effective an uptake of latex beads as a longer fragment, composed 
of 497 amino acids of the C-terminus, known as InvA497 [60]. 
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Recently, an in-depth mechanistic study was published exploring the 
cellular interaction between a liposomal bacteriomimetic system decorated with 
InvA497, and two epithelial cell lines (HEp-2 and Caco2) [90]. In this work, Labouta 
et al. demonstrated that InvA497-functionalised liposomes were able to mimic the 
cellular uptake mechanism of invasin-expressing Yersinia spp., and could also be 
used to effectively kill two different species of intracellular enteropathogenic 
bacteria [90, 91]. The potential of bacterial invasion factors such as invasin is 
therefore clear; however the full capabilities of bacteriomimetic still remain to be 
explored. In particular, the role of other system parameters, including the shape of 
the carrier system itself, has not yet been systematically studied with respect to 
invasin-functionalised drug carriers, or in terms of other bacteriomimetic systems. 
 
In general, the possible role of the carrier shape on the uptake of ligand 
functionalised nanoparticles has been mostly explored only with molecular 
modelling simulations. Different molecular dynamics simulation theories have been 
published in recent years, exploring the endocytosis of spheroid nanoparticles 
[220] as well as active uptake of ligand functionalised rod-like nanoparticles [221, 
222]. Simulations of receptor–ligand binding and nanoparticle transport across cell 
membranes have been studied, keeping constant the volume and ligand density of 
spherical and various aspherical (long and short rods, discs) nanoparticles [222]. 
According to these simulations, aspherical nanoparticles first orient toward the cell 
membrane in such a manner so as to maximise contact between particle-
associated ligands and corresponding cell surface receptors, leading to a second 
stage in which an invagination of the cell membrane occurs. The kinetic of this 
second stage depends on the shape and size of the nanoparticles, and on the 
release of free energy resulting from ligand-receptor binding [222]. 
 
Despite the conduction of such simulations and computational studies, the 
impact of particle shape on receptor mediated uptake has only been explored 
experimentally by Banerjee et al [188]. They were able to show that the presence 
of biotin functionalisation on the surface of aspherical nanoparticles enhanced 
uptake into human enterocytes [188]. The successful production and optimisation 
of aspherical InvA497-functionalised nanoparticles as detailed in the previous 
chapters therefore creates the possibility to answer these questions. 
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The following work was focused on exploring the uptake of aspherical 
InvA497-functionalised nanoparticles in comparison to spherical InvA497-
functionalised nanoparticles. The HEp-2 cell line was used as an in vitro epithelial 
cell model, and both confocal imaging and fluorescence-activated cell sorting 
(FACS) analysis were employed to assess the uptake. 
 
4.2 MATERIALS AND METHODS 
4.2.1 MATERIALS 
For the culturing of cells, Roswell Park Memorial Institute 1640 medium 
(RPMI 1640, Gibco, Carlsbad, USA) and foetal calf serum (FCS, Lonza, Cologne, 
Germany) were used. 
For cytotoxicity assessment, Triton X-100, 3-(4,5-di-methylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide reagent (MTT) and dimethyl sulfoxide (DMSO) were 
all purchased from Sigma-Aldrich (Steinheim, Germany) and phosphate buffered 
saline (PBS) from Gibco (Gibco, Carlsbad, USA) was used. 
Rhodamine-labeled Ricinus Communis Agglutinin I (Vector Laboratories, 
Inc., Burlingame, CA, USA), paraformaldehyde (Electron Microscopy Sciences, 
Hatfield, USA), 4',6-diamidino-2-phenylindole (DAPI, LifeTechnologies™, 
Darmstadt, Germany) and trypsin-EDTA (1x, Gibco, Carlsbad, USA), were 
employed to study the uptake. 
 
4.2.2 PREPARATION OF NANOPARTICLES AND 
FUNCTIONALISATION 
Spherical and aspherical PLGA nanoparticles (A and S respectively) were 
prepared as described in Chapter 3 using double emulsion and film stretching 
methods. 
Aspherical and spherical nanoparticles with InvA497 covalently coupled on 




4.2.3 CELL CULTIVATION 
Cells of the human larynx carcinoma-derived HEp-2 cell line were cultured 
in 75 cm2 flasks with RPMI 1640 medium, supplemented with 10% FCS. Cells 
were incubated at 37 °C and 5% CO2 and medium was changed every 2-3 days. 
Cells were split upon 80% confluency. 
 
4.2.4 CYTOTOXICITY STUDIES 
The cytotoxicity of the various nanoparticle formulations was assessed 
using the MTT assay. HEp-2 cells were seeded in 96-well plates (seeding density 
0.05x106 cells/well) three days before the experiment and were incubated with AI, 
SI, A or S (containing either 45 or 100 µg/ml of InvA497 in the case of AI and SI, 
and 1.06 or 0.63 mg/ml of PLGA/FA-PLGA) in RPMI 1640 medium, or with RPMI 
1640 medium neat or containing 2% Triton X-100 as controls, for 4 h at 37 °C and 
5% CO2. The supernatants were then removed from each well, and 10% (v/v) MTT 
reagent (5 mg/ml) in PBS was added and incubated with cells for a further 4 h. The 
medium was then removed. Formed formazan crystals were solubilised by 
incubation for 15 min in 100 μl of DMSO, and the absorbance of each well was 
measured with a plate reader (TECAN, Männedorf, Switzerland) at 550 nm. 
Measured absorbance values were then standardised to the employed positive 
control (2% Triton X-100 in RPMI 1640: 0% of cell viability) and cell viabilities were 
calculated in comparison to the used negative control (RPMI 1640 alone: 100% 
cell viability). 
 
4.2.5 UPTAKE STUDIES 
HEp-2 cells were seeded on 24-well plates (seeding density 0.2x106 
cells/well) the day before each experiment. After washing with PBS, cells were 
incubated with AI, SI, A, or S (containing 455 µg/ml of PLGA and, where 
appropriate, 60 µg/ml of InvA497 per sample) dispersed in RMPI 1640, for various 
intervals covering a total time period of 1-5 h. Nanoparticle uptake was then 




4.2.6 CONFOCAL IMAGING 
Cells treated with various nanoparticles for a period of 5 h were visualised 
using confocal imaging. After removing cell supernatants and washing with PBS to 
remove any extracellular nanoparticles, HEp-2 cell staining and fixing was carried 
out as follows. First, cell membranes were stained with 20 µg/ml Rhodamine-
labeled Ricinus Communis Agglutinin I; cells were then fixed with 3% 
paraformaldehyde in PBS. As a final step, cell nuclei were stained with DAPI 
diluted 1:50 000 (from a stock solution of 1 mg/ml) in PBS. Samples were then 
imaged via confocal laser scanning microscopy (CLSM, Leica TCS SP 8; Leica, 
Mannheim, Germany) using LAS X software (Leica Application Suite X; Leica, 
Mannheim, Germany). 
 
4.2.7 FACS ANALYSIS 
FACS analysis was used to quantify uptake of nanoparticles into HEp-2 
cells following incubation periods of 1, 2, 3, 4 and 5 h. Supernatants containing the 
various employed nanoparticles were first removed from plate wells, and cells 
were washed with PBS to remove non-internalised nanoparticles. Cells were then 
detached from plate wells by incubating with 100 µl of 0.05% trypsin-EDTA (10 min 
at 37 °C). To stop the trypsinisation, 900 µl of 2% FCS in PBS was added and the 
cells were centrifuged at 257 g for 5 min at 4 °C (Rotina 420R, Hettich Zentrifugen, 
Tuttlingen, Germany). Afterwards, 600 µl of 2% FCS in PBS was used to 
resuspend the pellets, and cell suspensions were stored at 4 °C until FACS 
analysis. FACS was performed using a BD LSRFortessaTM (BD Biosciences, 
Heidelberg, Germany) employing BD FACSDiva™ Software v8.0.1. Using an 
untreated negative control sample for reference, forward scatter (FSC) and side 
scatter (SSC) parameters were collected for live cells within each sample. Green 
fluorescence data (ex: 488 nm, filter: 530/30) were then collected from these living 
subpopulations, for a minimum of 10 000 events (cells) per sample.  
To determine the energy dependence of nanoparticle uptake, the same 
uptake study procedure and FACS analysis was applied, after incubating the 




4.2.8 STATISTICAL ANALYSIS 
Where appropriate, data are expressed as mean ± SE. Also where 
appropriate, data was analysed using SigmaPlot Version 11 (Systat Software Inc., 
San Jose, CA, USA) for statistical significance. Comparisons between groups were 
performed using Student´s t test (two-sided). Results were considered statistically 
significant at p values <0.05. 
 
4.3 RESULTS AND DISCUSSION 
As a preliminary test, the cytotoxicity of S, A, SI and AI formulations in a 
HEp-2 epithelial cell model was determined (Figure 4.1). Two concentrations were 
selected for testing - the highest concentration of InvA497 able to be administered 
without dilution (100 µg/ml), and a concentration same as the one employed in the 
case of the previously tested InvA497-functionalised liposome formulation (45 
µg/ml) [91] – in order to encompass the possible working range for further studies. 
A small reduction of the cells viability was noticed for the lowest concentrations, 






Figure 4.1: Cytotoxicity of nanoparticles. 
Spherical nanoparticles without or with functionalisation (S and SI) and the corresponding aspherical 
formulations (A and AI) were incubated with HEp-2 cells and the viability was measured via MTT 
assay. Results represent the mean ± SE (n=3). 
 
After testing the cell toxicity, the influence of particle shape on cellular 
uptake was then determined by incubating a non-toxic concentration of each 
nanoparticle formulation with HEp-2 cells, followed by CLSM (Figure 4.2) and 
FACS analysis (4.3). The HEp-2 cell line was consistently used for all experiments 
as this epithelial line expresses the β1 integrin receptor necessary for InvA497-
mediated uptake. 
As it was expected from the previous liposome studies [90], InvA497 
functionalisation was seen to enhance the uptake of both spherical and aspherical 
nanoparticles into HEp-2 cells. An increased uptake of SI and AI (Figures 4.2a and 
4.2b respectively) in comparison to S and A formulations (Figure 4.2c and 4.2d) at 
the 5 h endpoint of uptake studies was demonstrated, as noted from the increased 
presence of green fluorescence localised inside the cells in the case of SI and AI 
compared to S and A. Surprisingly for these last two formulations no appreciable 
uptake was seen due to the absence of InvA497 on the surface, in contrast with 
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the results obtained by other authors who tested uptake of spherical PLGA 
nanoparticles into Hep-2 cells [223, 224]. However as these uptake studies were 
done with PLGA particles marked with fluorescent molecules not covalently 
bounded to the polymeric core, the possible leakage of these fluorescent 
molecules out of the nanoparticle might have influenced and mislead the uptake 
study.  
The cross sections, shown in Figures 4.2a and 4.2b, demonstrate that SI 
and AI nanoparticles are able to penetrate inside the HEp-2 cells and not only 
adhere to cell surfaces. The green SI and AI nanoparticles are localised between 
the red cell membrane and the blue nucleus.  
 
 
Figure 4.2: Confocal microscopy images of the cellular uptake of nanoparticles. 
Uptake of aspherical (‘AI’, a) and spherical (‘SI’, b) nanoparticles functionalised with InvA497, as 
well as non-functionalised aspherical (‘A’, c) and spherical (‘S’, d) control nanoparticles into HEp-2 
cells is shown after 5 h of incubation at 37 °C. Cross sections for a and b are also shown, 
demonstrating the internalisation of the nanoparticles inside the HEp-2 cells. Red: HEp-2 cell 




As quantification of particle uptake and assessment of uptake kinetics could 
not be performed using the confocal instrument setup, FACS analysis was further 
employed (Figure 4.3). 
 
Figure 4.3: Quantification of intracellular uptake of nanoparticles into HEp-2 cells. 
The uptake of aspherical and spherical nanoparticles with or without InvA497 functionalisation (AI, 
SI, A and S) was tested at different time points, for a total period of 5 h. Results represent the mean ± 
SE (n=3); * indicates p value < 0.05 
 
Looking at the total extent of the particle uptake, internalisation of InvA497-
functionalised nanoparticles was found to be independent from nanoparticles 
shape. In particular, AI particles showed a slightly faster uptake compared to SI in 
the first hour. However the uptake ratio levelled out after 4 h, at approximately the 
same value of 66%. This levelling out appears to correspond to the plateau phase 
typically indicative of saturation of uptake-mediating receptors [225]. The uptake of 
InvA497-functionalised nanoparticles seems therefore not to be influenced from 
particle shape, as only a small difference in the kinetic of SI and AI cellular uptake 
was seen. Similar results were found for worm or rod-shaped particles, where the 
uptake into alveolar rat macrophages was lower compared with the spherical 
control [176].  
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In accordance with the confocal study, no appreciable uptake was noted for 
both A and S nanoparticles. Within the first 3 h, internalisation of AI and SI 
formulations was found to be significantly greater than A and S, independent of 
particle shape. 
In order to confirm that the uptake of the nanoparticles occurs through an 
energy dependent endocytosis uptake mediated by β1 integrin receptor, the uptake 
of the various nanoparticles into HEp-2 cells at 37 °C was compared with the 
uptake at 4 °C (Figure 4.4). As shown in literature, the energy-dependent uptake of 
functionalised nanoparticles at 4 °C is generally greatly reduced in comparison to 
uptake at physiological temperatures [90, 100]. 
 
Figure 4.4 Energy dependent uptake of nanoparticles on Hep-2 cells. 
Percentage of fluorescent HEp-2 cells after incubation of aspherical and spherical nanoparticles with 
or without InvA497 functionalisation (AI, SI, and A and S) with HEp-2 cells at 37° C and at 4° C was 
compared. Results represent the mean ± SE (n=3). *** indicates p value < 0.001 
 
As also previously shown for liposomes functionalised with InvA497 [90], a 
significant reduction in the percentage of nanoparticle-containing, fluorescent cells 
were observed for both AI and SI at 4° C compared with 37 °C. This suggests that 
both AI and SI are taken up via an energy-dependent mechanism due to the 
presence of InvA497 on the particle surface, as this internalisation pathway is 
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generally reduced at low temperature [100]. This also demonstrates the success of 
the coupling reaction between InvA497 proteins and terminal groups of PLGA, as 
only the correct oriented proteins are able to bind with the integrin protein on the 
surface of HEp-2 cells and penetrate via an energy-dependent mechanism. 
 
4.4 CONCLUSION 
The uptake of aspherical and spherical PLGA nanoparticles functionalised 
with InvA497, developed and optimised as detailed in chapter 3, was assessed in 
order to explore the influence of shape on receptor-mediated uptake and on 
normal uptake. 
After establishing a non-cytotoxic concentration of InvA497-functionalised 
nanoparticles, nanoparticles were incubated for a total time period of 5 h with HEp-
2 epithelial cells, and both confocal imaging and FACS analysis were conducted. It 
was noted using both measures that InvA497-functionalised aspherical and 
spherical nanoparticles exhibited a greater uptake compared with the non-
functionalised A and S formulations. Moreover, looking at the total kinetic uptake 
studies using FACS, internalisation of InvA497-functionalised nanoparticles was 
found to be independent on nanoparticle shape. In studies conducted at 4 °C no 
uptake of AI and SI into HEp-2 cells was noted, indicating that both aspherical and 
spherical InvA497 functionalised nanoparticles are taken up via an active energy 
dependent mechanism - in agreement with the natural mechanism by which 
invasin mediates bacterial uptake into host cells. 
This current work represents one of the first investigations into the influence 
of shape on cellular uptake of bacteriomimetic nanoparticles. Although the results 
obtained from the uptake of bacteriomimetic nanoparticles into epithelial cells are a 
somewhat unexpected result, the internalisation is only one of the factors which 
can influence the effectiveness of the system. Other nanoparticle characteristics 
can influence the efficacy against intracellular bacteria, including drug loading 
capacity and release behaviour. Therefore, to further investigate the influence of 
shape on bacteriomimetic systems, experiments with drug-loaded nanoparticles 
are required and will be discussed in the next chapter.  
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Parts of this chapter have been published in Pharmaceutical 
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functionalized Nanocarriers for Intracellular Delivery of Anti-




Although new antibiotics are being identified every day, the ability of 
pathogens to escape the immune system and resist the action of commonly used 
antibiotic drugs is continually evolving. Bacteria are normally divided into two 
groups depending on their localisation within a host: namely, extracellular and 
intracellular bacteria [226, 227]. For the first group, Streptococcus pyogenes and 
P. aeruginosa are the most common examples [226]. Classical examples of 
intracellular pathogens are S. flexneri, Listeria monocytogenes, M. tuberculosis 
and Salmonella enterica. This latter type of bacteria has the ability to invade into 
cells, like mammalian cells, and hide from the host immune system [21, 47]. 
Bacteria such as Yersinia spp. for example, are able to invade into M cells of the 
intestinal epithelium, to shelter inside membrane-bound vacuoles. This bacterium 
is then able to persist and multiply within the intestinal epithelial barrier, or infect 
distant mesenteric lymph nodes [228]. Other bacteria like S. flexneri, after 
penetrating through the host cell membrane, are able to escape from the vacuoles 
within which they are internalised and proliferate in the cell cytosol [22]. 
The hydrophilic nature of many antibiotics presents a major limitation to 
their efficacy against intracellular bacteria [229]. A classic example in this respect 
is gentamicin, a broad spectrum aminoglycoside antibiotic. While its broad 
spectrum of action creates the potential to utilise gentamicin as antibiotic therapy 
for a variety of infections, its highly hydrophilic nature prevents permeation across 
mammalian cell membranes [230]. Its clinical use is therefore limited to the 
treatment of intracellular bacterial infections, such as S. flexneri [231, 232]. 
Improvement in the nanoparticle field and studies on nanoparticle uptake 
could overcome the low permeation into the mammalian cells of hydrophilic 
antibiotics, like gentamicin. Moreover, active targeting could give a positive 
contribution to these ‘hard-to-treat’ infections. As discussed previously, the efficacy 
of bacteriomimetic nanoparticles against intracellular infections has been achieved 
by mimicking a β1 integrin-mediated uptake system from bacteria. Menina et al. 
[91] proved that liposomes functionalised with InvA497 and loaded with gentamicin 
were able to kill bacteria hidden inside HEp-2 cells, namely S. enterica and Y. 
pseudotuberculosis. This opens the possibility to explore the world of 
bacteriomimetic systems and their potential against intracellular infections. 
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The role of the physical characteristics of nanoparticles in drug delivery, as 
for example their shape, has not yet been systematically studied to the best of the 
author’s knowledge. There is clear evidence of the importance of the shape of 
colloidal structures in biological interactions, including the shape variation of 
bacteria themselves [94-96]. Modelling the bacterial shape variation in a 
bacteriomimetic system was therefore considered to be a logical yet largely un-
investigated step. 
As discussed in previous chapters a well-known technique was adapted in 
order to prepare polymeric nanoparticles with an aspherical shape; InvA497 was 
then coupled onto particle surfaces. The following work will be focused on the drug 
loading of this bacteriomimetic system with a lipophilic preparation of gentamicin, 
and efficacy testing of this system in an epithelial cell model infected with the 
common intracellular bacterium, S. flexneri. The efficacy of the aspherical 
bacteriomimetic system will be evaluated as throughout this thesis in comparison 
to drug-loaded bacteriomimetic nanoparticles composed of PLGA and also with 
InvA497 surface functionalisation, but which are spherical in shape. 
 
5.2 MATERIALS AND METHODS 
5.2.1 MATERIALS 
For nanoparticle preparation and characterisation, gentamicin sulphate, 
bis(2-ethylhexyl) sulfosuccinate sodium salt (AOT), sodium acetate, potassium 
chloride, calcium chloride, o-Phthaldialdehyde reagent (OPA), methanol, boric 
acid, 2-mercaptoethanol and potassium hydroxide were all purchased from Sigma-
Aldrich (Steinheim, Germany). 
For the anti-infective efficacy study and bacteria culture, RPMI 1640 (Gibco, 
Carlsbad, USA), PBS (Gibco, Carlsbad, USA), FCS (Lonza, Cologne, Germany), 
tryptic soy broth (TSB) medium (BD, Difco, Maryland), tryptic soy broth agar (TSA, 
BD, Difco, Maryland) and congo red (Fisher Chemical, Waltham, Massachusetts, 
USA) were used. 
For microbiological investigations and cytotoxicity assessment, Triton X-100 
(Sigma-Aldrich, Steinheim, Germany), a lactate dehydrogenase (LDH) activity 
cytotoxicity detection kit (Roche, Mannheim, Germany), RPMI 1640 medium 
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without phenol red (Gibco, Carlsbad, USA), fluorescein diacetate (FDA) and 
propidium iodide (both from Sigma-Aldrich, Steinheim, Germany) were employed. 
 
5.2.2 AOT-GENTAMICIN PREPARATION 
Gentamicin bis(2-ethylhexyl) sulfosuccinate sodium salt (AOT-gentamicin) 
was prepared according to Elizondo et al. [233] and Imbuluzqueta et al. [234]. For 
this process, 5 mol of the surfactant AOT was stoichiometrically complexed with 
the 5 ionisable amino groups of gentamicin via a hydrophobic ion pairing method 
(ionic complex molar ratio gentamicin:AOT 1:5). Briefly, 800 ml of a solution of 
AOT in dichloromethane (12.55 mg/ml) was mixed vigorously with a buffered 
aqueous solution (10 mM sodium acetate, 10 mM potassium chloride, 10 mM 
calcium chloride, pH 5.0) of gentamicin (4 mg/mL) for 3 h. The two formed phases 
were then separated by centrifugation (3 136 g , 5 min, RT; Rotina 420R, Hettich 
Zentrifugen, Tuttlingen, Germany), and, after evaporation of the organic phase 
(under vacuum for 15 min), AOT-gentamicin was recovered. 
 
5.2.3 FT-IR SPECTROSCOPY 
To compare the produced AOT-gentamicin with literature data from 
Imbuluzqueta et al. [234], a FT-IR spectrometer (Perkin Elmer system 2000) was 
used. For the measurements, dry AOT-gentamicin was employed and analysed. 
Spectra of dry AOT-gentamicin were collected in a range between 4000 and 650 
cm−1 with a resolution of 1 cm−1 (100 scans per sample). 
 
5.2.4 PREPARATION OF DRUG-LOADED NANOPARTICLES 
Spherical and aspherical PLGA nanoparticles loaded with AOT-gentamicin 
without InvA497 (SG and AG respectively) were produced as control groups. For 
SG, 3 mg of the ionic AOT-gentamicin complex was dissolved with the PLGA 
solution in ethyl acetate and the oil in water emulsion with PLGA was prepared as 
described in chapter 3. The excess of non-encapsulated AOT-gentamicin was then 
removed from formed nanoparticles using centrifugation (12 544 g for 12 min at 12 
°C). AG were prepared by stretching of SG nanoparticles, as described previously. 
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Where required, InvA497 was then coupled on the surface of spherical and 
aspherical AOT-gentamicin-loaded nanoparticles, also as described in chapter 2, 
to produce formulations denoted SIG and AIG respectively. 
The amount of AOT-gentamicin encapsulated in SG, AG, SIG and AIG 
nanoparticles was quantified as described by Imbuluzqueta et al. [234] using a 
fluorometric method based on the use of OPA reagent. 
Briefly, 0.2 g of OPA was first dissolved in 1 ml of methanol, 19 ml boric 
acid (0.4 M, pH 10.4) and 0.4 ml of 2-mercaptoethanol (14.3 M). After adjusting the 
pH to 10.4 using potassium hydroxide, 2 ml of this solution was mixed with 16 ml 
of methanol in order to have the final OPA solution. Standards were prepared 
using 1 ml of AOT-gentamicin solution in boric acid ranging in concentration from 0 
to 40 μg/ml, adjusted to pH 7.4. For nanoparticle samples, AOT-gentamicin was 
first extracted from the nanoparticles by stirring 0.5 ml of particle solution with 0.5 
ml of hydrochloric acid (0.1 M) for 8 h. The pH of the sample solutions was 
adjusted to pH 7.4 using potassium hydroxide and diluted to a volume of 1 ml with 
water. For the quantification, 1 ml solutions of standards and samples was mixed 
with 0.6 ml of methanol and 0.9 ml of the reagent solution (0.1 ml OPA reagent 
solution and 0.8 ml methanol) and then incubated for 10 min in dark. Afterwards 
the fluorescence was measured in a plate reader (TECAN, Männedorf, 
Switzerland) with an excitation of 344 nm and emission of 450 nm. 
The quantified amount of encapsulated AOT-gentamicin together with the 
initial amount of AOT-gentamicin used during nanoparticle preparation was used to 
calculate an encapsulation efficiency (EE%). After determining the dry mass of 
nanoparticle samples using the freeze dried (Alpha 2-4 LSC, Christ, Osterode am 
Harz, Germany), the loading capacity (LC%) was calculated as the amount of 




5.2.5 ZETA POTENTIAL 
The zeta potential of all aspherical and spherical formulations – 
functionalised and not-functionalised, drug loaded and empty – was determined by 
measurement of electrophoretic mobility using a Zetasizer Nano (Malvern 
Instruments Ltd, Worcestershire, United Kingdom). 
 
5.2.6 RELEASE TEST OF AOT-GENTAMICIN 
In order to achieve sink conditions and allow for determination of the 
release kinetics of AOT-gentamicin from various nanoparticle formulations, 
multiple samples of each formulation (containing 69.36 µg/ml of AOT-gentamicin) 
were centrifuged and resuspended in 7 ml of PBS pH 7.4. Samples were then 
incubated at 37 °C with stirring for a total of 24 h. At various intervals during this 
time, 2 samples of each nanoparticle formulation were taken and centrifuged (1 
680 g, 10 min). After centrifuging, the amount of released AOT-gentamicin in the 
produced supernatant was measured using the aforementioned fluorometric 
method [234]. 
At the 2 h timepoint of release studies, samples of aspherical nanoparticle 
formulations were also taken and analysed for their shape using SEM (Zeiss EVO 
HD 15, Carl Zeiss AG, Oberkochen, Germany) at an accelerating voltage of 5 kV. 
Samples were imaged after drying overnight and following sputter coating 
(Quorum Q150R ES, Quorum Technologies Ltd, Laughton, United Kingdom) with 
gold. 
 
5.2.7 CELL CULTIVATION 
As described in chapter 4, cells of the human larynx carcinoma-derived 
HEp-2 cell line were cultured in 75 cm2 flasks using RPMI 1640 medium, 
supplemented with 10% FCS. Cells were incubated at 37 °C and 5% CO2 and 




5.2.8 CYTOTOXICITY OF AOT-GENTAMICIN LOADED 
NANOPARTICLES AND AOT-GENTAMICIN ALONE 
An LDH cytotoxicity detection kit was used to assess the viability of HEp-2 
cells following treatment with AG, SG, AIG and SIG as well ad AOT-gentamicin 
alone, in accordance with the manufacturer’s instructions. This kit measure the 
activity of the LDH enzyme, which catalyses the interconversion of pyruvate and 
lactate. The activity of this enzyme is high when there is cell damage, for example 
as a result of exposure to a toxic agent. 
Briefly, HEp-2 cells were seeded in a 96-well plate (seeding density 0.05 x 
106 cells/well), cultured for 72 hours and, after washing with PBS, incubated for 4 h 
(at 37 °C and 5% CO2) with different concentrations of nanoparticle formulations 
(concentration of AOT-gentamicin 5-120 µg/ml, corresponding concentration of 
InvA497 12-50 µg/ml) dispersed in RPMI 1640 medium without phenol red. As 
controls, cells incubated with RPMI 1640 medium alone (negative control) and 
RPMI with 2% Triton X-100 (positive control) were used. Cell supernatants were 
then removed and incubated with the provided LDH reagent for 3 min at RT. the 
absorbance of cell supernatants, indicative of LDH activity, was then read with a 
plate reader (TECAN, Männedorf, Switzerland) at a wavelength of 490 nm. To 
calculate cell viability, the absorbance measured in each sample supernatant was 
standardised to that of the positive control (Triton X-100) and calculated in 
comparison to that of a negative control (RPMI-treated cells). 
 
5.2.9 BACTERIA CULTURE 
S. flexneri (strain M90T, kindly supplied by the Department of Molecular 
Infection Biology, HZI, Braunschweig, Germany) bacteria were stored on sterile 
TSA agar plates supplemented with 0.08% (w/v) congo red at 4 °C. Before each 
experiments, virulence factor-expressing colonies of S. flexneri had been cultured 
and incubated in glass tubes containing 10 ml of TSB overnight at 37 °C, with 





5.2.10 INVASION ASSAY OPTIMISATION 
The virulence of S. flexneri bacteria in different growth phases was first 
tested, in order to find parameters that would provide an optimal balance between 
rate of invasion of Hep-2 cells and used bacterial inoculum. Bacteria had been 
cultured as described above in order to reach the stationary phase and, before 
infecting cells, bacteria in exponential phase were prepared by incubating a freshly 
diluted culture of S. flexneri in TSB medium at 37 °C for 2 h. Both bacteria in 
stationary phase (overnight culture) and in exponential phase (2 h culture) were 
used to infect previously cultured HEp-2 cells in a 24-well plate (seeding density 
0.2 x 106 cells/well) after resuspending both cultures in RPMI 1640 medium. 
Different multiplicities of infection (MOI - bacteria:HEp-2 cell ratio) were also 
investigated. To enhance bacteria sedimentation onto the HEp-2 cells, plates were 
centrifuged (6 708 g for 5 min) following addition of bacteria, and were afterwards 
incubated for 2 h in a humidified incubator at 37 °C and 5% CO2 atmosphere, in 
order to allow for bacterial adhesion and cellular invasion. Cells were then washed 
with PBS to remove the excess of bacteria. In order to kill any remaining 
extracellular bacteria, cells were further incubated for 2 h with RPMI medium 
containing 50 µg/ml of gentamicin. Killed extracellular bacteria were then removed 
by washing of cells with PBS. Intracellular bacteria were counted after lysing the 
infected HEp-2 cells with 0.01% Triton X-100, and plating the cell lysate in serial 
dilutions in sterile agar plates. Plates were incubated overnight at 37 °C to allow 
for bacterial growth, before counting the final number of bacterial colony forming 
units (CFU). After multiplying by relevant dilution factors, the CFU of S. flexneri 
were expressed as a percentage of the number of colonies from the inoculum, 
termed the percentage of invasion. 
 
5.2.11 CYTOTOXICITY OF INFECTED HEP-2 AFTER 
NANOPARTICLES TREATMENT 
Confocal imaging was used to assess the continued viability of infected 
HEp-2 cells after treatment with AIG, SIG, AG, SG, AI, SI, A and S, as well as 
AOT-gentamicin alone. After seeding and culturing HEp-2 cells in a 24-well culture 
plate for imaging for 24 h (seeding density 0.2 x 106 cells/well), the cells were 
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infected with S. flexneri in the exponential phase and at an MOI of 25:1 dispersed 
in RPMI 1640 medium. After washing with PBS, the infected cells were incubated 
for 2 h with RPMI medium containing 50 µg/ml of gentamicin for extracellular 
bacteria killing, as described above. After washing with PBS to remove dead 
extracellular bacteria, cells were incubated with loaded and unloaded spherical 
and aspherical nanoparticles, with or without InvA497-functionalisation. (120 µg/ml 
of AOT-gentamicin, 49 µg/ml of InvA497 and 3.7 mg/ml of PLGA/FA-PLGA where 
appropriate – standardised by employing drug-free functionalised or drug-free non-
functionalised nanoparticles of corresponding shape where necessary) for 3 h at 
37 °C and 5 % CO2. As controls AOT-gentamicin alone was used, as well as RPMI 
1640 medium alone, and RPMI with 2% Triton X-100. Following incubation with 
formulations, HEp-2 cells were washed twice with PBS and then incubated with a 
20 µg/ml solution of FDA (stock solution 1 mg/ml in acetone) and 40 µg/ml 
propidium iodide (stock solution 1 mg/ml) in PBS. The two substances stained 
respectively live cells (green) and dead cells (red). CLSM (Leica TCS SP 8; Leica, 
Mannheim, Germany) was employed for imaging of cell samples. The negative 
control (infected cells without treatment and incubated with RPMI medium) and 
positive control (2% Triton X-100) samples were used to give a qualitative 
comparison of cell viability. 
 
5.2.12 EFFICACY STUDY 
The efficacy of the InvA497-functionalised, AOT-gentamicin loaded 
nanoparticle systems in killing of intracellular S. flexneri was tested. After seeding 
HEp-2 cells on 24 well plates (seeding density 0.2 x 106 cells/well), infecting these 
with S. flexneri and killing the extracellular bacteria as described in section 5.2.10, 
different types of nanoparticles (AIG, SIG, AG, SG, AI, SI, A and S) as well as 
ATO-gentamicin alone were added and incubated for 3 h. Concentrations used 
were the same as those described in the LDH-based cytotoxicity assay (section 
5.2.8). After washing twice with PBS, HEp-2 cells were incubated with 0.01 % 
Triton X-100 in order to lyse the cells. Dilutions of the cell lysate were plated in 
sterile TSB-agar plates and the plates were incubated overnight at 37 °C. The 
CFU of S. flexneri were counted and, after multiplying by relevant dilution factors, 
the percentage of remaining intracellular bacteria (expressed as CFU from each 
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cell lysate relative to the CFU of bacteria used for initial infection – the inoculum) 
was calculated. The efficacy was expressed as percentage of bacteria killing, 
using the values for each formulation treatment group normalised to the 
percentage of remaining intracellular bacteria in untreated cell samples. 
5.2.13 STATISTICAL ANALYSIS 
Where appropriate, data are expressed as mean ± SE. Also where 
appropriate, data was analysed using SigmaPlot Version 11 (Systat Software Inc., 
San Jose, CA, USA) for statistical significance. Comparisons between groups were 
performed using Student´s t test (two-sided) or one-way ANOVA with post-hoc 
Bonferroni adjustment for experiments with more than two subgroups. Results 
were considered statistically significant at p values <0.05. 
 
5.3 RESULTS AND DISCUSSIONS 
AOT-gentamicin was prepared according to Elizondo et al. [233] and 
Imbuluzqueta et al. [234] and loaded into spherical and aspherical nanoparticles. 
This lipophilic preparation of gentamicin was used to overcome the low 
encapsulation of unmodified gentamicin found to occur within PLGA nanoparticles, 
due to the hydrophilic nature of the drug. Simple mixing of gentamicin and the 
surfactant AOT, followed by solvent evaporation, leads to formation of a highly 
lipophilic preparation, as a result of electrostatic interaction between the sulfonate 
part of AOT and the five amine groups present within each gentamicin molecule, 
(Figure 5.1a and b respectively). The successful formation of the AOT-gentamicin 
preparation was confirmed by comparing IR spectra obtained in the current work, 





Figure 5.1: Chemical structure and IR spectrum of AOT-gentamicin. 
Chemical structure of AOT (a) and gentamicin (b) molecules used to form AOT-gentamicin complex. 
c) IR spectrum showing typical peaks and bands (black boxes) due to the presence of the surfactant 
AOT as well as gentamicin were observed in the formed AOT-gentamicin complex. 
 
Typical peaks and bands were recognised in obtained IR spectra of the 
AOT-gentamicin complex, when comparing to the results of Imbuluzqueta et al. In 
particular: a band between 3000 and 2800 cm-1 denoting alkyl chain vibrations; 
bands at 1734, 1201 and 1157 cm-1, indicative of the AOT ester groups; and a 
band at 1036 cm-1, for the presence of sulfonyl group. The same bands were found 
by Imbuluzqueta et al. [234], demonstrating the successful formation of the ion-
complex AOT-gentamicin. 
 
For the preparation of SG and AG nanoparticles, freshly prepared AOT-
gentamicin was included in the organic solvent solution with PLGA and standard 
particle preparation as described in previous chapters was then conducted. 
InvA497 was then coupled to the surface of SG and AG to produce SIG and AIG 
respectively. For all loaded formulations, the amount of encapsulated AOT-





Figure 5.2 Chemical characterisation of drug-loaded nanoparticles. 
(a) The encapsulation efficiency (EE%) and loading capacity (LC%) of AIG and SIG, as well as AG 
and SG is shown. Results represent the mean ± SE (n=3). 
 
A reduction of approximately 10% with respect to the EE% of AIG 
(approximately 26%) and AG (approximately 38%) formulations was observed 
relative to their spherical counterparts (around 37% for SIG and 45% for SG) most 
likely as a result of the stretching procedure and the numerous washing steps 
done during the preparation procedure. A drop of approximately 15% was also 
observed in terms of LC%. Even with this reduction however, aspherical 
nanoparticle formulations still demonstrate a good ability to incorporate AOT-
gentamicin, with an EE% more than 25% and LC% higher than 35%. 
Despite the small differences in amount of encapsulated drug, the amount 
of InvA497 functionalisation for AIG and SIG was found to be slightly higher than 
for the AI and SI formulations (Figure 5.3) (see chapter 3). The amount of InvA497 
on AIG and SIG might have been due to an increase of the absorbed fraction of 
protein on the nanoparticles surface - caused by the presence of AOT-gentamicin 





Figure 5.3 InvA497 functionalisation for drug-loaded nanoparticles. 
The amount of InvA497 coupled to the surface of AIG and SIG formulations was shown to be 
comparable. Results represent the mean ± SE (n=3). 
 
The encapsulation of AOT-gentamicin within both aspherical and spherical 
formulations also had an effect on the surface charge (Figure 5.4). The zeta 
potential of drug-loaded formulations was found to be significantly higher than that 
of the empty formulations, while no difference was found between the surface 
charge of functionalised and non-functionalised nanoparticles. This difference in 
surface charge between the loaded nanoparticles (AIG and SIG) and the empty 
formulations (AI and SI) could provide a possible explanation for the different 
amounts of InvA497 coupled on the surface of these two formulation types. The 
decrease in the magnitude of surface charge found for drug-loaded formulations 
(AIG and SIG) could have led to a higher amount of the adsorbed InvA497 protein 
on the surface compared with the empty formulation. 
Surprisingly no difference in the zeta potential was found between 
aspherical and spherical formulations, indicating that the shape of these PLGA 





Figure 5.4 Zeta potential of bacteriomimetic nanoparticles. 
The zeta potential of aspherical and spherical InvA497-functionalised nanoparticles loaded with 
AOT-gentamicin (AIG and SIG respectively), aspherical and spherical nanoparticles loaded with 
AOT-gentamicin (AG and SG), aspherical and spherical InvA497-functionalised nanoparticles (AI 
and SI) and aspherical and spherical nanoparticles (A and S), was measured by electrophoretic 
mobility.*** indicates statistical significance with a p value < 0.001 for AIG, SIG, AG and SG versus 
AI, SI, A and S. Data shows the mean ± SE (n=9). 
 
The in vitro release profiles of AOT-gentamicin from AIG, SIG, AG and SG 




Figure 5.5 In vitro release kinetics.  
AOT-gentamicin release was measured from AIG, SIG, AG and SG over 24 h in PBS at 37 °C. The 
insert graph shows release over the first 250 min. *Indicates statistical significance with p value < 
0.05 for AIG or AG versus SIG or SG. Results represent the mean ± SE of three independent 
experiments, each with duplicate samples. 
 
Within the first two hours, a slightly greater burst release was noted from 
AG and AIG compared to SIG and SG. Although this small difference was noted in 
the early time points, the overall release profile seems to be independent from the 
shape. Moreover the presence of InvA497 on the surface of both aspherical and 
spherical nanoparticles doesn´t influences the drug release. This observed 
difference in the kinetics could potentially be explained by an accompanying 
change in shape of aspherical nanoparticles during this time period, as observed 





Figure 5.6 Morphology of asphercial nanoparticles during the release study. 
Representative SEM images of AIG (a) and AG (b) after 2 h of incubation at 37 °C during drug 
release studies are shown. 
 
The observed recovery of the original spherical geometry seen for both AIG 
and AG nanoparticles could potentially have induced an initial faster release of 
AOT-gentamicin from these nanoparticles. This slightly accelerated release profile 
is unlikely to be an effect of degradation [235]. Shape recovery, and therefore the 
faster drug release, might be caused by the change of the surface tension of the 
nanoparticles, which is influenced by the shift of pH from 6 to 7.4 and the addition 
of PBS salt. A simlar shape change of non-spherical nanoparticles was previously 
reported by Yoo et al. [157] as a result of a reduction in pH, who however did not 
test drug release from such particles. Moreover such shape change in constant pH 
condition was never observed and the associated release was not seen in other 
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formulations. The implications of this shape-dependent release on the later 
efficacy study need to be further investigated. 
In order to determine a suitable dose of AOT-gentamicin alone as well as 
incorporated in nanoparticles for later efficacy studies, the cytotoxicity of AIG, SIG, 
AG and SG nanoparticles and as well AOT-gentamicin alone (G) was tested in 
HEp-2 cells using an LDH assay (Figure 5.7). 
 
 
Figure 5.7 Cytotoxicity of drug-loaded nanoparticles. 
Viability of HEp-2 cells after 4 h treatment with AIG, AG, SIG and SG was tested, as well as after 
treatment with free AOT-gentamicin (G) as control. Results represent the mean ± SE (n=3). 
 
For both nanoparticles and free drug, cytotoxicity was tested over a range of 
AOT-gentamicin concentrations, which encompassed the concentration of 
gentamicin contained within the previously tested InvA497-functionalised 
liposomes (50 µg/ml of gentamicin) [91]. No toxic effect on HEp-2 viability was 
found at any of the tested concentrations, with treatment at all concentrations 
showing a reduction in HEp-2 viability of less than 5%. Surprisingly no difference in 
cytotoxicity was found between aspherical and spherical formulations. From this 
data, formulations containing 30 µg/ml, 60 µg/ml and 120 µg/ml of AOT-gentamicin 
were selected for testing in efficacy studies. 
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After nanoparticle characterisation and preliminary cytotoxicity in vitro study, 
the anti-infective efficacy of bacteriomimetic nanoparticles against intracellular S. 
flexneri was evaluated. 
First an in vitro model of HEp-2 cells infected with S. flexneri was 
established and optimised, in order to provide an optimal balance between 
bacterial invasion percentage and used bacterial inoculum. In particular the 
invasion capacity of S. flexneri bacteria in different growth phases and at various 
MOI was tested, in order to guarantee the highest invasion percentage with the 
lowest possible amount of bacteria and to avoid HEp-2 cell damage. Therefore S. 
flexneri cultures were grown to the exponential or stationary growth phase and 
afterwards HEp-2 cells were infected for 2 h with varying MOI. Following the 
infection stage, extracellular bacteria were killed using free gentamicin, which, due 
to its poor cell permeability, cannot penetrate inside the cells. As described 
previously [230], gentamicin is commonly used for this purpose in the 
establishment of in vitro cell models containing intracellular bacteria, as it 
guarantees killing of only extracellular bacteria and the survival of the intracellular 
fraction. The infection percentage of intracellular bacteria resulting from incubation 
with S. flexneri at different growth phases and at different MOI was then 





Figure 5.8 Optimisation of the infection of Hep-2 cells with S. flexneri  
Percentage of infection after 4 h incubation of S. flexneri with HEp-2 cells with different MOI, using 
bacteria in either the exponential phase or stationary phase, is shown. Results represent the mean ± 
SE (n=6). 
 
Bacteria in the exponential phase and at an MOI of 25:1 were determined to 
provide the optimal conditions for promoting uptake of intracellular bacteria, 
resulting in a reproducible number of intracellular bacteria while also giving the 
highest actual number of intracellular CFU (approximately 1800). Therefore these 
infection parameters were employed for the following efficacy studies. 
 
After  establishing the optimal conditions for intracellular infection of HEp-2 
cells with S. flexneri, the viability of HEp-2 cells following both bacterial infection 
and treatment with various nanoparticle formulations and free drug was tested 
using a live-dead viability assay and confocal imaging (Figure 5.8). The highest 
concentration of AOT-gentamicin (120 µg/ml) found to be non-toxic in the previous 
LDH assay, was employed. Due to the presence of intracellular S. flexneri and 
therefore the inability to use conventional cytotoxicity methods (such as LDH assay 
or MTT method) to selectively measure the viability of HEp-2 cells, a qualitative 
method with calcein AM and ethidium homodimer-1 was employed to indicate the 
viability of infected Hep-2 cells after nanoparticles treatment. In this method, the 
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green dye calcein AM is able to stain only healthy cells and the red dye ethidium 
homodimer-1 is able to stain the nuclei exposed in damaged cells. 
 
 
Figure 5.9 Viability of S. flexneri infected cells after nanoparticles treatment. 
Hep-2 cells infected with S. flexneri were treated for 3 h with AIG (a), AI (b), AG (c), A (d), SIG (e), SI 
(f), SG (g), S (h) and G (i) followed by live-dead staining and confocal microscopy imaging in order to 
visualise continued cell viability. Cell viabilities were observed in comparison to negative control 
(infected cells without treatment) (j) and a positive control (infected cells treated with 2% Triton X-
100) (k). Green=live cells; red=dead cells. 
 
No effect on HEp-2 cell viability following both infection with S. flexneri and 
treatment with various nanoparticle formulations was seen, due to the presence of 
clear green stained cells; however, a slight toxic effect, evident from the red colour 
of some cells and the duller green appearance of other cells (Figure 5.9 i), was 
observed when infected cells were treated with free AOT-gentamicin. Incorporation 
of AOT-gentamicin into nanoparticles seems therefore to have a protective effect. 
Despite the slight cytotoxicity of the free drug and considering the comparable 
safety of all the nanoparticles formulations on epithelial cells, in efficacy studies, 
infected cells were treated with three different doses of free AOT-gentamicin as 
well as AOT-gentamicin encapsulated inside nanoparticles (30 µg/ml, 60 µg/ml 




Figure 5.10: Efficacy study of nanoparticles against intracellular S. flexneri. 
Percentage of killing of intracellular S. flexneri after 2 h treatment with the aspherical (AIG, AI, AG, 
A) and spherical (SIG, SI, SG, S) formulations, as well as free drug (G) using three different drug 
doses (30 µg/ml, 60 µg/ml and 120 µg/ml) is shown. *** indicates statistical significance with a p 
value < 0.001 for AIG versus AI, AG, A, and G, and SIG versus SI, SG, S and G. Data shows the mean 
± SE of 3 independent experiments, each employing duplicate samples. 
 
For the efficacy study, HEp-2 cells infected with intracellular S. flexneri 
bacteria were treated with freshly prepared AOT-gentamicin-loaded and InvA497-
functionalised nanoparticles, of both aspherical and spherical shape (AIG and 
SIG). For comparison, formulations which were not loaded with drug but were 
surface functionalised (AI and SI) as well as drug-loaded formulations without 
surface InvA497 (AG and SG) and empty, non-functionalised formulations (A and 
S) were tested. Free AOT-gentamicin (G) was also employed. In the case of both 
AIG and SIG, a dose dependent reduction in the number of intracellular bacteria 
was observed. As expected from their poor cell-penetrating ability in the previous 
uptake study [91], formulations without InvA497 functionalisation (AG and SG) 
were not able to effectively kill intracellular S. flexneri; as expected, nor were 
control formulations without drug (AI and SI, as well as A and S). Surprisingly, 
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lipophilic free AOT-gentamicin was also not able to kill intracellular S. flexneri, as 
probably a high degree of lipophilicity is not the only characteristic controlling 
penetration into mammalian cells.  
Comparing AIG and SIG, the trend in the percentage of intracellular killed bacteria 
was found to be dependent on the concentration. The higher concentration (120 
µg/ml of AOT-gentamicin) of the bacteriomimetic nanoparticles leads to a greater 
killing comparing with the other two tested concentrations. Moreover a small but 
significant difference in bacteria killing was also found between the AIG and SIG 
formulations at the highest tested drug concentration - at which AIG systems led to a 
higher killing of intracellular bacteria in comparison to spherical bacteriomimetic 
nanocarriers (Figure 5.10). 
 
 
Figure 5.11: Direct comparison of bacterial killing of AIG and SIG. 
Bacteria killing resulting from the treatment of S. flexneri-infected HEp-2 cells with AIG and SIG at a 
120 µg/ml dose of AOT-gentamicin is shown. * indicates p value < 0.05. Data shows the mean ± SE of 
3 independent experiments, each employing duplicate samples 
 
The slightly higher beneficial effect of the aspherical nanoparticles could be 
explained with the initial burst release of the AOT-gentamicin from the AIG 
polymeric systems (see Figure 5.5), however the extent of the difference between 
the percentage of killed bacteria of AIG and SIG is too modest for evaluating the 
effect of the shape. 
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However this difference still indicates a promising application of aspherical 
systems functionalised with InvA497 systems for treating intracellular infection.  
Independently by the shape, nanoparticles functionalised with InvA497 




Aspherical and spherical nanoparticles loaded with a lipophilic preparation 
of gentamicin were prepared and functionalised with InvA497 in order to 
investigate the efficacy of the bacteriomimetic systems. Chemical characterisation 
of aspherical and spherical formulations showed an EE% and LC% higher than 
25% and 35% respectively for the aspherical nanoparticles and higher than 35% 
and 50% for the spherical ones. Surprisingly the in vitro release profile of AOT-
gentamicin from aspherical and spherical nanoparticles showed an initial burst 
release from both InvA497-functionalised and non-functionalised aspherical 
systems within the first two hours, which was hypothesised to be a result of the 
shape recovery of aspherical nanoparticles, observed to occur within the same 
time frame. 
After establishing a non-toxic range of concentrations of the drug-loaded 
systems, and optimising the procedure for infecting HEp-2 cells with S. flexneri, the 
aspherical and spherical nanoparticles, with or without functionalisation and drug 
loaded or unloaded were tested in such an infection model. A dose dependent 
killing effect was found for both AIG and SIG, which additionally showed killing 
greater ability to kill intracellular S. flexneri comparing with all the other 
formulations. Moreover, comparing the efficacy of AIG and SIG at the highest 
employed dose, a significantly greater killing of intracellular S. flexneri was noted 
for the aspherical drug-loaded functionalised nanoparticles. However the modest 
magnitude of this difference highlights the considerable remaining scope for carrier 
system development and probing of shape effects – namely, optimisation of aspect 
ratio and maintenance of asphericity - in order to further enhance intracellular 
bacterial killing 
Taken together, these results demonstrate that the presence of InvA497 on 
the surface of nanoparticles in combination with encapsulation of AOT-gentamicin 
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is able to increase the ability of PLGA-based delivery systems to effectively treat of 
infected epithelial cells. Moreover, nanoparticles with aspherical shape seem to be 








The objectives of the presented study were related to the question: what is 
the potential in drug delivery of a bacteriomimetic system with an aspherical shape 
and InvA497 protein conjugated on the surface? The work was focused on 
investigating the influence of shape on the physico-chemical characteristics of 
bacteriomimetic systems, using InvA497-functionalised polymeric nanoparticles 
with spherical and aspherical morphology, and on evaluating the potential of both 
spherical and aspherical drug-loaded systems for accessing and killing intracellular 
bacteria. 
The current work represents the first in-depth study into the impact of 
modifying the surface of nanoparticulate delivery systems through the use of 
bacteria-derived invasion molecules, in combination with changing their shape 
from spherical to non-spherical. 
 
In the first part of the thesis, suitable methods for the preparation of 
spherical and, in particular, aspherical nanoparticles were selected. With respect to 
aspherical nanoparticles, the film stretching method was chosen as a more 
reproducible and suitable method for the present work. After designing a stretching 
apparatus and testing and optimising preparation conditions, PLGA nanoparticles 
with an aspherical shape were successfully obtained. In parallel, a strong focus 
was placed on the physical and chemical characterisation of the aspherical 
particles, with specific areas of interest being imaging of the particles using SEM 
and confocal microscopy, and on evaluation of different methods for determining 
particle dimensions and shape, such as SEM and AF4. Analysis of the size 
distribution of major and minor axes of the aspherical nanoparticles was conducted 
using these techniques. 
The second part of this work was focused on the surface functionalisation of 
both spherical and aspherical nanoparticles with the bacterial invasion protein 
fragment InvA497, followed by preliminary in vitro uptake studies. Particularly for 
aspherical nanoparticles, the method of particle preparation was further adapted in 
order to achieve a high number of InvA497 molecules on the surface of 
nanoparticles, without changing their aspherical shape. With an appropriate 
quantification method, the amount of coupled InvA497 and the molecules of 
InvA497 per nanoparticle were measured. Moreover, a 3D model of aspherical and 
spherical nanoparticles functionalised with InvA497 was generated. 
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Afterwards the uptake of both bacteriomimetic systems (spherical and 
aspherical) was tested in HEp-2 cells, and compared with the non-functionalised 
polymeric nanoparticles. It was found that InvA497-functionalised nanoparticles 
were internalised better than the systems without InvA497. The presence of the 
protein on the surface of the nanoparticles was therefore able to enhance the 
particle uptake. Comparing the two bacteriomimetic formulations, a small 
difference was observed in the uptake, however considering the general uptake 
profile, the two shapes didn´t exhibit differences in receptor-mediated uptake. 
In the last part of this work, the aspherical and spherical systems were 
loaded with an anti-infective agent, AOT-gentamicin. After characterisation of both 
types of nanoparticles and functionalisation of the surface with InvA497, the in vitro 
release of AOT-gentamicin from the nanoparticles was tested. Although a small 
difference was found in the kinetic release of the aspherical and spherical 
nanoparticle, considering the general release profile, the two shapes didn´t exhibit 
a substantial difference. After testing the in vitro cytotoxicity of the drug-loaded 
systems and developing an intracellular infection model of S. flexneri, the efficacy 
of aspherical and spherical InvA497-functionalised nanoparticles against 
intracellular bacteria was investigated. When loaded with an anti-infective and 
tested for their efficacy in an intracellular infection model, bacteriomimetic systems 
had a markedly improved killing effect in comparison to non-functionalised 
systems. Instead the shape of bacteriomimetic systems was found to have a small 
influence on the efficacy against intracellular S. flexneri. This last aspect is of great 
interest for future work. 
. 
Bacteriomimetic systems mimicking the invasive surface functionality as 
well as the shape of numerous intracellular bacteria therefore appear to be a 
promising approach for delivering anti-infective drugs into infected cells, combating 
such intracellular pathogens by mimicking their own infection pathway. 
The demonstrated promise of these systems creates interesting 
perspectives for controlling a number of intracellular pathogens of the gastro-
intestinal tract. Further work should be focus on the optimisation of these systems 
for the respective pathogens and diseases typical of such specific routes of 
administration. The killing efficacy of the bacteriomimetic systems should be tested 
using a more specific model, which can represent better the intestinal barrier - like 
  
122 
a triple culture model that mimics the intestinal barrier and has the integrin receptor 
exposed – or against other enteropathogenic bacteria - like Yersinia or Listeria.  
On the other hand the potential of bacteriomimetic delivery systems to kill 
intracellular infections might as well be explored in other types of bacteria, which 
infect different epithelial tissues and organs, such as the pulmonary epithelium. 
 
Moreover a more deep mechanistic evaluation, looking at the intracellular 
pathway of the InvA497-functionalised nanoparticles, should be conducted in order 
to study the interaction between bacteria and nanoparticles. 
 From the preparation point of view, the orientation and distribution of 
InvA497 on the surface of both spherical and aspherical nanoparticles should be 
explored. These are important parameters for the InvA497-dependent uptake and 
for the interaction with the integrin receptor. Although the data are not showed in 
the present thesis, different techniques were already employed for this purpose 
(TEM, ESEM and Raman microscopy), using also InvA497-specific antibody, 
without positive results. In particular, changing the distribution of InvA497 on the 
surface of aspherical nanoparticles (protein concentrated in certain areas) and 
studying its influence on intracellular uptake and antibacterial effect would be an 






7.1 CALCULATION OF SURFACE OCCUPANCY 
 
gyration radius of InvA497= 5.5mm (Yasara[210])   
      
aspherical (spheroid)   spherical (sphere) 
r1 (b) = 151.5 nm  r1= 95.6 nm  
r2 (a) = 60.35 nm    




   
 
 
     
A(spheroid)= 95603.7676 nm2  A(sphere)= 114848.585 nm2 
      
A(InvA497)= n(InvA497) * 2πr(gyration)2 A(InvA497)=n(InvA497)*2πr(gyration)2 
n(InvA497)= 198   n(InvA497)= 235 
A(InvA497)=37633.1384 nm2  A(InvA497)= 44665.5936 nm2 
  A/A= 0.39 (= occupancy)    A/A= 0.39 (=occupancy) 
 
7.2 SCRIPT FOR POVRAY 3.7 
The following script was written for PovRay 3.7 to be used as an *.inc file: 
 
//------------------ random functions standard include file------------------ 
#include "rand.inc" //random functions provided by PovRay 
#include "invasin_tex.inc" //appearance of invasin molecules 
#include "invasin_surf03.inc" //coordinates of invasin surface vertices, 
generated as an export file from YASARA using pdb entry 1CWV 
#declare Random_1 = seed (124323); //initializing random coordinate #1 
#declare Random_2 = seed (1335); //initializing random coordinate #2 
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#declare NP_fin_01 = finish {ambient 0 emission 0 diffuse 1 brilliance 1 
subsurface { translucency <4.69, 3.69, 2.69> }specular 0.15 roughness 0.5} 
//appearance of particles 
#declare NP_tex_03 = texture {pigment {granite colour_map {[0.0, srgb 
<0.6,0.6,0.61>] [1.0, srgb <0.8,0.8,0.81>]}} normal { granite 0.1 } finish {NP_fin_01} 
scale 0.1} texture {pigment {color srgbt<1,1,1,1>} normal { granite 0.5 } finish 
{ambient 0 emission 0 diffuse 0 brilliance 1 specular 0.5 roughness 0.01} scale 
0.1} //layered texture of particles 
#declare invasin_tex_01 = texture {pigment {rgb <0.6,0.7,0.5>} finish 
{phong 0.4}} //appearance of the space occupied by invasins – only seen when 
included as an object 
//INVASINS================================================
=========== 
#declare inv_scaled = object {invasin_surf scale 0.000001163  translate 
<0.0007,0,-0.033>} //model of invasin molecule, scaled to PovRay units 
#declare inv_vol = cylinder{ <-0.0186/2,0,0>, <0.0186/2,0,0> ,0.00342 
texture {invasin_tex_01}} //Volume which invasins occupy 
//ASPHERICAL_NP==========================================
========== 
#declare NP_basic_shape01 = //---------------------------------------------------------
-----------------  
         object{ //Spheroid(CenterVector,   RadiusVector Rx,Ry,Rz )   
                        Spheroid(<0,0,0>,       <0.303/2,0.1207/2,0.1207/2> ) 
                        texture{ NP_tex_03} scale<1,1,1>  rotate<0, 0,0> 
translate<0,0.00,0> 
                   } //shape of the aspherical naoparticle 
#declare NP_surface01 = difference {object {NP_basic_shape01 scale 
1.01} object {NP_basic_shape01 scale 1.005}} //Volume in which invasins are 
placed 
 #declare invasins_rand01 = merge { 
    #local Nr = 0;     // start 
    #local EndNr = 198; // number of invasins on surface 
    #while (Nr< EndNr) 
      object {inv_scaled 
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             rotate VRand_On_Sphere(Random_2)*180 
             translate VRand_In_Obj( NP_surface01, Random_1)*1 
             texture{ invasin_tex_01 } //interior_texture { PA_tex_01int } // end of 
texture 
            } // end of object 
    #local Nr = Nr + 1;  // next Nr 




#declare NP_basic_shape02 = sphere {<0,0,0>, 0.1912/2 texture{ 
NP_tex_03} scale<1,1,1>  rotate<0, 0,0> translate<0,0.00,0>} //shape of the 
spherical naoparticle 
#declare NP_surface02 = difference {object {NP_basic_shape02 scale 
1.01} object {NP_basic_shape02 scale 1.005}} //Volume in which invasins are 
placed 
#declare invasins_rand02 = merge { 
    #local Nr = 0;     // start 
    #local EndNr = 235; // number of invasins on surface 
    #while (Nr< EndNr) 
      object {inv_scaled 
             rotate VRand_On_Sphere(Random_2)*180 
             translate VRand_In_Obj( NP_surface02, Random_1)*1 
             texture{ invasin_tex_01 } //interior_texture { PA_tex_01int } // end of 
texture 
            } // end of object 
    #local Nr = Nr + 1;  // next Nr 
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